WO2002055531A1 - Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy - Google Patents

Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy Download PDF

Info

Publication number
WO2002055531A1
WO2002055531A1 PCT/HR2002/000001 HR0200001W WO02055531A1 WO 2002055531 A1 WO2002055531 A1 WO 2002055531A1 HR 0200001 W HR0200001 W HR 0200001W WO 02055531 A1 WO02055531 A1 WO 02055531A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydrogen
group
sep
fluorine
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/HR2002/000001
Other languages
French (fr)
Inventor
Mlanden Mercep
Milan Mesic
Linda Tomaskovic
Marijana Komac
Boska Hrvacic
Stribor Markovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pliva Farmaceutika dd
Original Assignee
Pliva Farmaceutika dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to HU0500180A priority Critical patent/HUP0500180A3/en
Priority to SK979-2003A priority patent/SK9792003A3/en
Priority to JP2002556599A priority patent/JP4474101B2/en
Priority to EA200300781A priority patent/EA007061B1/en
Priority to PL363478A priority patent/PL207636B1/en
Priority to IL15667302A priority patent/IL156673A0/en
Priority to US10/250,934 priority patent/US7446097B2/en
Priority to AT02729470T priority patent/ATE462713T1/en
Priority to EEP200300293A priority patent/EE05333B1/en
Priority to BR0206347-6A priority patent/BR0206347A/en
Priority to CA002434009A priority patent/CA2434009C/en
Priority to DE60235794T priority patent/DE60235794D1/en
Application filed by Pliva Farmaceutika dd filed Critical Pliva Farmaceutika dd
Priority to HK04108052.4A priority patent/HK1065320B/en
Priority to EP02729470A priority patent/EP1351973B1/en
Priority to UA2003076135A priority patent/UA77166C2/en
Publication of WO2002055531A1 publication Critical patent/WO2002055531A1/en
Anticipated expiration legal-status Critical
Priority to US12/211,213 priority patent/US7928078B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to novel compounds represented by the structure I and pharmaceutical preparations thereof for the treatment of inflammatory diseases in humans and animals.

Description


  



  CONJUGATES OF IMMUNE CELL SPECIFIC MACROLIDE COMPOUNDS WITH ANTI-INFLAMMATORY
COMPOUNDS FOR IMPROVED CELLULAR TARGETING OF ANTI-INFLAMMATORY THERAPY
Technical problem
The present invention relates to new anti-inflammatory compounds represented by the general structure   I,    to their salts and solvates, to processes for their preparation and to the use of these compounds in the treatment of inflammatory diseases and conditions in humans and animals.



   Prior art
Anti-inflammatory medicaments could be classified into those of steroid and of nonsteroid type. Steroid anti-inflammatory compounds are still the most effective ones in the treatment of inflammatory diseases and conditions such as asthma, chronic obstructive pulmonary disease, inflammatory nasal diseases such as allergic rhinitis, nasal polyps, intestinal diseases such as Crohn's disease, colitis, ulcerative colitis, dermatological inflammations such as eczema, psoriasis, allergic dermatitis, neurodermatitis, pruritis, conjunctivitis and rheumatoid arthritis. In addition to the excellent potency and effectiveness, medicaments of this type also possess numerous unfavourable effects e. g. on carbohydrate metabolism, calcium resorption, secretion of endogenous corticosteroids as well as on physiological functions of hypophysis, adrenal cortex and thymus.

   Hitherto developed steroids are highly effective against inflammation conditions and processes since they inhibit many inflammation mediators whereas their systemic unfavourable effects are diminished. Patent applications WO 94/13690, WO 94/14834, WO 92/13873 and WO   92/13872    disclose so-called"soft"steroids or hydrolysable corticosteroids designed for topical application on the inflammation site, whereas their systemic unfavourable effect is diminished due to the instability of"soft"steroids in serum, wherein the active steroid very rapidly hydrolizes into the inactive form.

   An ideal steroid, however, without unfavourable effects in a long-term and continuous treatment as required for the control of diseases such as asthma or Crohn's disease has yet to be found and it has been worked intensively on finding and developing steroids with an improved therapeutic profile.



  Nonsteroid anti-inflammatory medicaments of different mechanisms act on particular inflammation mediators, thus providing a therapeutical effect. Due to different action mechanisms and differences in the inhibition of particular inflammation mediators, the steroid and nonsteroid medicaments possess different profiles of anti-inflammation effects, hence in particular conditions they are used alternatively or preferentially.
Unfortunately, nonsteroid anti-inflammatory medicaments are not absolutely specific either and demonstrate unfavourable effects when used in greater concentrations or over long periods. It is known that many nonsteroid anti-inflammatory medicaments act as inhibitors of endogenous COX-1 enzyme, which is very important in maintaining the integrity of the gastric mucosa.

   Thus, the use of these medicaments causes injuries of the gastric mucosa and bleeding in numerous patients. For some anti-inflammatory compounds (theophylline) it is known that their therapeutic index is very narrow, which limits their usage.



  Macrolide antibiotics accumulate within different cells of organism, especially within phagocyte cells such as mononuclear peripheral blood cells, peritoneal and alveolar macrophages as well as in the liquid surrounding the bronchoalveolar epithelium (Glaude R. P. et al, Antimicrob. Agents   Chemother.,    33 1989,277-282; Olsen K. M. et al, Antimicrob. Agents   Chemotlier.,    40 1996,2582-2585). Moreover, in the literature also relatively weak inflammatory effects of some macrolides are described. Thus, there has recently been described the anti-inflammatory effect of erythromycin derivatives   (J : Antimicrob. Chemother., 41,    1998,37-46; WO 00/42055) and azithromycin derivatives (EP 0283055).

   An anti-inflammatory effect of some macrolides is also known from in vitro and in vivo studies in experimental animals such as at zimosane-induced peritonitis in mice   (J : Antimicrob. Chemother. 30,    1992, 339-348) and at endotoxine-induced neutrophil accumulation in rat trachea (J.



  Immunol.   159,    1997,3395-4005). The modulating effect of macrolides upon cytokines such as interleukin 8 (IL-8)   (Am. J. Respir. Crit. Care. Med. 156,    1997,266-271) or interleukin 5 (IL-5) (EP 0775489 and EP 0771564) is known as well.



  Technical Solution
Compounds of the structure I differ from hitherto known ones in their new action mechanism characterized by selective accumulation in the organs and cells targeted in the above-mentioned inflammation conditions and diseases. Such action of the new compounds represented by the structure I arises from the macrolide portion M due to the said specific pharmacokinetic properties. Such pharmacokinetic properties enable the compounds represented by the structure I to act exclusively in the inflammation site just in the inflammation cells themselves by inhibiting the production of inflammation mediators. In such a manner the unfavourable systemic effect of both corticosteroids and nonsteroid anti-inflammatory compounds is avoided.

   After topical application the molecules rapidly accumulate in inflammation cells, wherein they act by inhibiting the production of cytokines and chemokines as well as other inflammation mediators and thus suppressing the inflammation. According to the known and established prior art, the compounds represented by the structure I, which are the object of the present invention, their pharmacologically acceptable salts and pharmaceutical preparations comprising them have hitherto not been described.



  Moreover, none of the compounds being the object of the present invention has been described either as an anti-inflammatory substance or as an inhibitor of eosinophilic accumulation in inflammation tissues.



  The object of the present invention are new compounds, their salts and solvates represented by the structure I
EMI3.1     
 wherein M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, A represents an anti-inflammatory subunit that can be steroid or nonsteroid and L represents a chain linking M and A, as well as an improved therapeutic effect of these compounds in treating inflammation diseases and conditions.



  More specifically, this invention relates to compounds, their salts and solvates represented by the structure I, wherein M represents a macrolide subunit represented by the formulas
EMI4.1     
 wherein   Rl    is hydrogen or a methyl group,
R2 and R3 are both hydrogen or together form a bond, or
R2 is an amino group represented by the substructur  -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that   R3    is then hydrogen,   R4    is a hydroxyl or cladinosyl group represented by the structure
EMI4.2     
 
R4 and R5 may also together form a carbonyl group, with the proviso that   Rl    is then a methyl group;

  
EMI5.1     
 wherein   Rl    is hydrogen or a methyl group,   R2 and R3    are both hydrogen or together form a bond, or
R2 is an amino group represented by the substructure  -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen,   R4 may    be any alkyl group having 1-4 carbon atoms, preferably a methyl group;

  
EMI5.2     
 wherein   Rl    is hydrogen or a methyl group,   R2 and    R3 are both hydrogen or together form a bond, or
R2 is an amino group represented by the substructur  -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having   1-6    carbon atoms, with the proviso that R3 is then hydrogen,   R4 is    a hydroxyl or cladinosyl group represented by the structure
EMI6.1     

R4 and R5 may also together form a carbonyl group, with the proviso that Ri is then a methyl group;

  
EMI6.2     
 wherein   Rl    is hydrogen or a methyl group,
R2 and R3 are both hydrogen or together form a bond, or
R2 is an amino group represented by the substructur  -NR'R'' wherein R'and R"may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen,
R4 is a hydroxyl or cladinosyl group represented by the structure
EMI7.1     
 wherein   Rl    is hydrogen or a methyl group,   R2 and R3 are    both hydrogen or together form a bond, or
R2 is an amino group represented by the substructur  -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen,

     R4 is    a a hydroxyl or cladinosyl group represented by the structure 
EMI8.1     

R5 may be any alkyl group having 1-4 carbon atoms, preferably a methyl group;
EMI8.2     
 wherein   Rl    is hydrogen or an acetyl group,
R2 and R3 are both hydrogen or together form a bond, or
R2 is an amino group represented by the substructur  -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen,
R4 is a hydroxyl or cladinosyl group represented by the structure
EMI8.3     
   R5    may be any alkyl group having 1-4 carbon atoms, preferably a methyl group, and A is an anti-inflammatory subunit represented by the formulas:

  
EMI9.1     
 wherein Z represents oxygen or a NH group, Rl is hydrogen or a hydroxyl or O-acyl or 0-alkyl group,
R2 represents hydrogen or a methyl group, which may be oriented in   a-or    p-position,
Xi is hydrogen or halogen,
X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine,   1,    2-position may represent a double or a single carbon-carbon bond;
EMI9.2     
 wherein Z represents oxygen or a NH group, Ri is hydrogen or a hydroxyl or O-acyl or 0-alkyl group,
R2 represents hydrogen or an acyl group,
Xi is hydrogen or halogen,
X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine;

  
EMI10.1     
 or stereoisomeric forms thereof, wherein the 1,2-position represents a saturated or unsaturated double bond, wherein Z represents oxygen or a NH group,   Rl    is hydrogen, a straight or branched hydrocarbon chain having 1-4 carbon atoms,
R2 is hydrogen, a straight or branched hydrocarbon chain having 1-10 carbon atoms, with the proviso that   Rl    and R2 are not simultaneously hydrogen,
Xi is hydrogen or halogen,
X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine;

   
EMI11.1     
 or stereoisomeric forms thereof, wherein the 1,2-position represents a saturated or unsaturated double bond, wherein Z is oxygen or a NH group,
Rl is hydrogen, a straight or branched hydrocarbon chain having 1-4 carbon atoms,
R2 is hydrogen, a straight or branched hydrocarbon chain having 1-10 carbon atoms with the proviso that   Rl    and R2 are not simultaneously hydrogen,
Xi is hydrogen or halogen,
X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine;

  
EMI11.2     
 or stereoisomeric forms thereof, wherein the 1,2-position represents a saturated or unsaturated double bond,   R,    is hydrogen, a straight or branched hydrocarbon chain having 1-4 carbon atoms,
R2 is hydrogen, a straight or branched hydrocarbon chain having 1-10 carbon atoms with the proviso that   Rl    and R2 are not simultaneously hydrogen, 
Xi is hydrogen or halogen,
X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine, preferably fluorine;

  
EMI12.1     
 wherein Z is oxygen or a NH group, Rl is hydrogen or a hydroxyl group with a free hydrogen or a hydroxyl group or O-acyl or 0-alkyl group,
R2 is hydrogen or a methyl group, which may be oriented in a-or   (3-position,   
R3 is hydrogen or a radical of an acid having 1-4 carbon atoms,
Xi is hydrogen or halogen,
X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine, preferably fluorine, 1,2-position may represent a double or single carbon-carbon bond, and L is a chain with the   formula-CRIR2 (CR3R4) nCR5R6-,    wherein Rl, R2, R3,   R4,      R5, R6    may be hydrogen,   Cl-C4-alkyl,    aryl, metoxy, halogen, hydroxy or mercapto groups, wherein n is 1-10, and one or   more-CR3R4-groups    may be substituted with oxygen,

   sulphur, an aromatic nucleus or an amino group additionally bearing hydrogen or a Cl-C4 alkyl or aryl group, or Ri, R2, R3, R4, R5, R6 may also together form one or more double or triple bonds in a chain, thus forming alkenyl or alkinyl, with the proviso that at least one methylene group is situated at the end of linking L group. 



  The chain covalently links subunits M and A via functional groups such as amides, ureates, carbamates, ethers, esters or via alkyl-alkyl or carbon-carbon bonds.



  The terms used in the present invention are defined as stated hereinafter if not specified otherwise.



     "Alkyl"means    a monovalent alkane (hydrocarbon), wherefrom a radical is derived, which may be a straight-chain one, a branched-chain one, a cyclic one or a combination of straight-chain and cyclic hydrocarbons and branched-chain and cyclic hydrocarbons. Preferred straight-chain or branched-chain alkyls include methyl, ethyl, propyl, iso-propyl, butyl, sec-butyl and t-butyl groups. Preferable   cycloalkyls    include cyclopentyl and cyclohexyl groups. Alkyl also represents both a straight-chain or a branched-chain alkyl group including or being interrupted by a cycloalkyl portion.



     "Alkenyl"means    a hydrocarbon radical, which is a straight-chain one, a branchedchain one, a cyclic one or a combination of straight-chain and cyclic hydrocarbons and branched-chain and cyclic hydrocarbons and comprises at least one double carboncarbon bond. Mainly ethenyl, propenyl, butenyl and cyclohexenyl groups are meant thereby. As already mentioned above for"alkyls", also alkenyls may be straight-chain, branched-chain or cyclic ones, where a part of the alkenyl group may include double bonds and may also be substituted when a substituted alkenyl group is in question.



  Alkenyl also represents both a straight-chain or a branched-chain alkenyl group including or being interrupted by a cycloalkenyl portion.



     "Alkynyl"means    a hydrocarbon radical, which is a straight-chain or a branched-chain one and includes at least one and at most three triple carbon-carbon bonds. Mainly ethynyl, propynyl and butynyl groups are meant thereby.



  "Aryl"means an aromatic ring such as phenyl group, substituted phenyl or similar groups as well as rings that are fused such as naphtyl and the like. Aryl includes at least one ring having at least   6    carbon atoms or two rings having together 10 carbon atoms, possessing alternating double (resonance) bonds between carbon atoms (mainly phenyl and naphtyl rings). Aryl groups may be additionally substituted with one or two substituents, which may be halogen (fluorine, chlorine or bromine) and hydroxy,   C1-   
C7 alkyl, Cl-C7 alkoxy or aryloxy,   Cl-C7    alkylthio or arylthio, alkylsulfonyl, ciano or amino groups.



  A further object of the present invention relates to a process for the preparation of compounds represented by the structure   I.   



  These compounds can be prepared from the corresponding steroid part represented by the general structures Al to A6, wherein all radicals and symbols have the meanings as defined for substructures Al to A6, and macrolide intermediates represented by the general structures MI to M6 by linking them via appropriate functional L groups. In an analogous manner, it is also possible to prepare compounds represented by the structure I with nonsteroid anti-inflammatory subunits via their free functionalities suitable for linkage.



  From carboxylic acids of steroid subunits represented by the structures Al to A4 and
A6, which are prepared as described in the literature   (Suzuki,    T. et al, Chem.   Soc.,   
Perkin Trans. 1 1998,3831-3836), (McLean, H. M. et al,   J Pharm. Sci.    1994,83, 476-480), (Little, R. J. et al, Pharm. Res. 1999,16,961-967), (Kertesz D. J. et al,   J.   
Org. Chem. 1986,51,2315-2328), (Bodor N. S.   US Paterct 4, 710, 495,    1987), a compound of the general formula I can be prepared, where the activation with carboxydiimide and benzotriazole (HOBT) in anhydrous dichloromethane in the presence of a base such as triethylamine at room temperature in a flow of argon is used for the formation of an amide bond (Scheme 1). 
EMI15.1     


<tb>



   <SEP> R2 <SEP> L
<tb> R <SEP> N-NH2 <SEP> HA
<tb>  <SEP> HO
<tb>  <SEP> HO. <SEP> /A
<tb>  <SEP> +
<tb>  <SEP> Oh
<tb>  <SEP> ¯.,"i <SEP> OH
<tb>  <SEP> 0
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> Mil", <SEP> N
<tb>  <SEP> N
<tb>  <SEP> dichloromethane%
<tb>  <SEP> OH
<tb>  <SEP> triethylamine
<tb>  <SEP> (CH3) <SEP> 2N <SEP> (CH2) <SEP> 3N=C=NCH2CH3
<tb>  <SEP> r
<tb>  <SEP> R2 <SEP> L
<tb>  <SEP> R3 <SEP> N-NH
<tb>  <SEP> Ho
<tb>  <SEP> ho
<tb>  <SEP> 0 <SEP> oil. <SEP> RJO <SEP> 0
<tb>  <SEP> OH
<tb>  <SEP> 0
<tb>  <SEP> H0 <SEP> i
<tb>  <SEP> O
<tb>  <SEP> I
<tb> 
Scheme 1
When the linking of macrolide subunits to the steroid subunits takes place via an ester bond, the synthesis is performed via the macrolide intermediate M7. 
EMI16.1     




   Scheme 2
Esterification in position 2'of the macrolide can be performed by the reaction with a halogen-substituted acid in dry dichloromethane in the presence of pivaloyl chloride, triethylamine and dimethylaminopyridine (DMAP), thus forming intermediates M7 for linking with carboxylic acids of the subunit A (Scheme 2).



  Such an intermediate can further react with the carboxylic functionality of subunit A in case of a steroid subunit such as represented by the structures Al to A4 and A6.



  The reaction is performed in dry DMF in the presence of a base such as potassium carbonate   (K2CO3)    in a flow of argon, yielding a potassium salt of the acid, which in the reaction with the macrolide intermediate gives a compound I of the present invention (Scheme 3). 
EMI17.1     




   Scheme 3
When the macrolide subunit means M2 (a macrolide free of cladinose in position 3), it is also possible to perform the coupling with an anti-inflammatory subunit A via an ester bond, whereat the preparation of intermediates   M8    and M9 is necessary (Scheme 4). 
EMI18.1     


<tb>



   <SEP> 0
<tb>  <SEP> Ry <SEP> R2 <SEP> Ret <SEP> R2
<tb>  <SEP> N <SEP> N
<tb>  <SEP> OH <SEP> acetic <SEP> anhydride <SEP> OH
<tb>  <SEP> O <SEP> OR <SEP> l0 <SEP> O
<tb> Ho <SEP> HO
<tb>  <SEP> ¯ <SEP>  > . <SEP> OA <SEP> IOH <SEP> CH2cl2 <SEP> 4 <SEP>   <  <SEP> OH
<tb>  <SEP> M8
<tb>  <SEP> M8
<tb>  <SEP> Br <SEP> (CH2) <SEP> nCOOH
<tb>  <SEP> 09
<tb>  <SEP> R4 <SEP> l <SEP> 82
<tb>  <SEP> N <SEP> 0/1, <SEP> R3
<tb>  <SEP> OH
<tb>  <SEP> Oh
<tb>  <SEP> HO.",,,
<tb>  <SEP> OR, <SEP> tio <SEP> o
<tb>  <SEP> HO. <SEP> Ill.,
<tb>  <SEP> 1 <SEP> O, <SEP> O
<tb>  <SEP> M9
<tb>  <SEP> m <SEP> 9
<tb> 
Scheme 4
Esterification with the carboxylic group of subunit A occurs selectively due to the protected 2'hydroxyl group of macrolide M9, which is also reactive. 
EMI19.1     




   Scheme 5
The synthesis of a compound of the structure I from a macrolide subunit indicated by
Ml is performed from an intermediate, whose synthesis is described in Agouridas C.,
J. Med. Chem. 1998,41,4080-4100, in the manner and by the use of reagents described therein. From said intermediate M10 a compound of the structure I is synthesized by the reaction with an anti-inflammatory subunit A bearing a carboxylic functionality by the use of potassium carbonate in dry DMF at room temperature (Scheme 6). 
EMI20.1     




   Scheme 6
The compounds of the general structure I comprising a compound M3 as the macrolide unit are synthesized by linking a modified anti-inflammatory unit AS with a macrolide M3, which is prepared according to the already mentioned method (Agouridas C., J.   Med. Chem.    1998,41,4080-4100). The anti-inflammatory intermediate A8 is prepared from an acid of the anti-inflammatory compound and a corresponding protected diamine (Boc-protection only from one side) in the presence of hidroxybenzotriazole and EDC in a suitable solvent, preferably dichloromethane or
DMF. After obtaining the corresponding amide A7, a deprotection of the terminal amino group is performed by the use   of TFA    in dichloromethane at room temperature (Scheme 7).
EMI21.1     




   Scheme 7
The intermediate obtained according to the Scheme 7 is reacted in acetonitrile in a flow of nitrogen with a macrolide subunit M12, which is activated by carboxydiimide and comprises protected hydroxyl groups in positions 2'4" (Scheme 8). 
EMI22.1     




   Scheme 8
If the steroid subunit is described as indicated for the general structure A5, wherein all groups and radicals have the meanings as described in the above-mentioned definitions, the coupling reaction with the macrolide group is performed by the esterification of the intermediate A9 obtained according to the literature (HU   55409)    and of the macrolide hydroxyl group (Scheme 9). 
EMI23.1     


<tb>



   <SEP> 0
<tb>  <SEP> (CH2) <SEP> nCOOH
<tb> o
<tb>  <SEP> fu <SEP> c
<tb>  <SEP> .... <SEP> fl% <SEP> CR1R2
<tb>  <SEP> I-i <SEP> O <SEP> C <SEP> H3 <SEP> C..
<tb>



   <SEP> C <SEP> H <SEP> w . <SEP> 0 <SEP> + <SEP> H <SEP> 
<tb>  <SEP> j
<tb> L/0 <SEP> + <SEP> HOw
<tb>  <SEP> J <SEP> 1
<tb>  <SEP> X2 <SEP> pivaloyl <SEP> chloride
<tb>  <SEP> A9 <SEP> Zu
<tb>  <SEP> t <SEP> CH2CI2
<tb>  <SEP> 
<tb>  <SEP> 0
<tb>  <SEP> zu <SEP> (CH2) <SEP> CHO
<tb>  <SEP> 0
<tb>  <SEP> Chop
<tb>  <SEP> HO <SEP> C.....,
<tb>  <SEP> f <SEP> f,, <SEP> o/C <SEP> R1 <SEP> R2
<tb>  <SEP> J <SEP> 1
<tb>  <SEP> X2
<tb> 
Scheme 9
A further object of the present invention relates to the use of compounds of the general structure I as anti-inflammmatory,   anti-anaphylactic    and immunomodulating agents, which, depending on the inflammation site, can be administered in different ways such as percutaneously, orally, buccally, rectally, parenterally or by inhalation when a topical application within the respiratory tract is intended.



  A further object of the present invention relates to the preparation of such pharmaceutical forms of compounds to achieve the optimal bioavailability of the active compound I. For percutaneous administration the compound I can be prepared in a form of an ointment or a cream, a gel or a lotion. Ointments, creams and gels can be formulated by the use of a water or oil base under the addition of an appropriate emulgator or gelling agent, when a gel form is formulated. The formulation is especially significant for respiratory inhalation, wherein the compound I can be in the form of an aerosol under pressure.

   For all forms of aerosol formulations it is recommended to micronise the compound I, which has been previously homogenised in lactose, glucose, higher fatty acids, sodium salt of dioctylsulfosuccinic acid or, most preferably, in carboxymethyl cellulose, in order to achieve the size of 5   llm    for the greatest number of particles. For the inhalation formulation the aerosol can be mixed with a propellant serving for spraying the active substance.



  The compound I for inhalation application can be applied in the form of a dry powder with micronised particles.



  The compound can also be incorporated in a formulation for treating Crohn's disease, where it can be administered orally or rectally. The formulation for oral administration must be formulated so as to enable the bioavailability of the compound in the inflammation part of the intestine. This can be achieved by different combinationa of delayed release formulations. The compound I can also be used in the treatment of
Crohn's disease and intestine inflammation disease if the compound is applied in the form of a clyster, wherefor a suitable formulation can be used.



  The appropriate preparations of the compounds that are the object of the present invention can be used in the prophylaxis or treatment of different diseases and pathological inflammatory conditions including asthma, chronic obstructive pulmonary disease, inflammatory nasal diseases such as allergic rhinitis, nasal polyps, intestinal diseases such as Crohn's disease, colitis, intestine inflammation, ulcerative colitis, dermatological inflammations such as eczema, psoriasis, allergic dermatitis, neurodermatitis, pruritis, conjunctivitis and rheumatoid arthritis. 



  The therapeutic effect of the compounds of the present invention was determined in the following in vitro and in vivo experiments.



  Assay of binding to the human glucocorticoid receptor
The gene for alpha isoform of human glucocorticoid receptor was cloned by reverse polymerase chain reaction. The total RNA was isolated from human peripheral blood lymphocites according to the instructions of the manufacturer (Qiagen), transcripted into cDNA with AMV reverse transcriptase (Roche) and the gene was multiplied by specific primers 1)   5'ATATGGATCCCTGATGGACTCCAAAGAATCATTAACTCC3'    2) 5'ATATCTCGAGGGCAGTCACTTTTGATGAAACAGAAG3'
The obtained reaction product was cloned into XhoI/BamHI site of Bluescript KS plasmid (Stratagene), subjected to sequencing by dideoxy fluorescent method with   M13    and   M13rev    primers (Mycrosynth) and then it was cloned into XhoI/BamHI site   of pcDNA3.    1 hygro (+) plasmid   (Invitrogen)

  .      1      x      105      COS-1    cells were seeded onto a 12-well plate (Falcon) in DMEM medium (Life Technologies) with 10 % FBS (Biowhitaker) and cultivated up to a 70 % confluence at   37  C    in an atmosphere with 5 %   C02.    The medium was removed and 1   Flg of DNA,    7   Ill    of PLUS reagent and 2   Ill    of Lipofectamine (Life Technologies) in 500   u. l DMEM    were added per well. The cells were incubated at   37  C    in an atmosphere with   5 % CO2    and after 5 hours the same volume of 20 %   FBS/DMEM    was added.

   After 24 hours the medium was completely changed. 48 hours after the transfection, the test compounds in different concentrations and 24 nM   [3H] dexamethasone (Pharmacia)    in DMEM medium were added. The cells were incubated for 90 minutes at   37  C    in an atmosphere with 5 %   C02,    washed three times with PBS buffer (Sigma), cooled to   4'C (pH = 7.    4) and then lyzed in Tris buffer (pH = 8.0) (Sigma) with 0.2 % SDS (Sigma). After the addition of
UltimaGold XR (Packard) scintillation liquid, the residual radioactivity was read in a   Tricarb    (Packard) p-scintillation counter. 



  Compounds 9,10 and 27 are able to compete with radioactive dexamethasone in the binding site on the glucocorticoid receptor.



  Assay of steroid introduction into cells
CHO and COS-1 cells were cultivated up to confluence in 75 cm2 flasks in Hamm F 12 medium (Life Technologies) with 10 % FBS (CHO) or in DMEM medium with 10 % FBS (COS-1).   1pM    of radioactive compound 10 with total 2   LCi    activity was added onto the cells and it was incubated for 90 minutes at   37  C    in an atmosphere with   5 % CO2.    The cell supernatant was collected, the cells were lysed and then the radioactivity in the cell lysate as well as in the cell supernatant was read. The compound 10 was able to accumulate in the cells in a greater concentration than in the supernatant.



  Assay of inhibition of mouse. T-cell hybridoma 13 proliferation as a result of apoptose induction
In a 96-well plate triplicates of test steroid dilution in   RPMI    medium   (Imunoloski    zavod) with 10 % PBS were performed. To the solutions of compounds 20 000 cells per well were added and incubated overnight at   37  C    in an atmosphere with   5 % C02,    then 1   IlCi    of   [3H] thymidine (Pharmacia)    was added and it was incubated for additional 3 hours. The cells were harvested by sucking over GF/C filter (Packard).



  Onto each well 30   Ill of Microscynt O    scintillation liquid (Packard) were added and the incorporated radioactivity was measured on a   {3-scintillation    counter (Packard).



  The specifity of apoptose induction by glucocorticoids was proven by antagonising the proliferation inhibition with mifepristone (Sigma).



  Compounds 8,9,10 and 27 demonstrated an inhibition of cell hybridoma 13 proliferation.



  Assay of inhibition of interleukin-2 production 
Onto a 96-well plate (Nunc) 15 ng   of 2C 11    antibodies (Pharmingen) per well were added and left to adsorb in PBS buffer (pH = 7.4) overnight at   4  C.    PBS was removed, the plate was washed with RPMI medium and then 50 000 cells per well were added and incubated in the medium with and without a dilution of the test compounds. The concentration of IL-2 in the supernatant was measured by ELISA specific for mouse IL-2 (R & D Systems).



  The compounds 9,10 and 27 demonstrate an inhibition of interleukin-2 production induced by the stimulation via CD3 receptor.



  Table 2
EMI27.1     


Compound <SEP> Binding <SEP> to <SEP> the <SEP> Induction <SEP> of <SEP> H13 <SEP> Inhibition <SEP> of <SEP> IL-2
<tb>  <SEP> glucocorticoid <SEP> cells <SEP> apoptose <SEP> synthesis
<tb>  <SEP> receptor
<tb> 5 <SEP> ND
<tb> 8 <SEP> +
<tb> 9 <SEP> +
<tb> 8 <SEP> + <SEP> + <SEP> +
<tb> 9 <SEP> + <SEP> + <SEP> +
<tb>  <SEP> 0 <SEP> + <SEP> + <SEP> +
<tb> 11 <SEP> ND
<tb>  <SEP> 27 <SEP> + <SEP> + <SEP> +
<tb> dexamethasone <SEP> + <SEP> + <SEP> +
<tb> 
ND-not determined
Model of croton oil-induced ear edema
Male Sprague Dawley rats with body weight of 200-250 g were randomly divided into groups, marked and the inital ear thickness was measured with a digital caliper. 



  To the control group 50   u. l    of solvent (acetone, Kemika) per ear were applied. In the same manner also the test compound in a dose of 1 mg/ear or the standard   (1    mg/ear of dexamethasone,   Krka)    dissolved in acetone were applied. Thirty minutes later an ear edema was induced with 20 % croton oil (Sigma). The maximum intensity of the inflammation was reached five hours after the application of croton oil. The percentage of the ear edema inhibiton was determined by compariing the ears of the treated animals and of the control ones. In this model the compound 10 was tested, which demonstrated a similar activity as the tested standard.



  Model of lung eosinophilia in mice
Male Balb/C mice with a body weight of 20-25 g were randomly divided into groups.



  They were sensibilized by an i. p. injection of ovalbumine (OVA, Sigma) on zero day and on the fourteenth day. On the twentieth day the mice were subjected to a provocative test by i. n. application of OVA (positive control or test groups) or PBS (negative control). 48 hours after i. n. aplication of OVA, the animals were anesthetized and the lungs were rinsed with 1 ml of PBS. The cells were separated on
Cytospin 3 cytocentrifuge (Shandon). The cells were stained in Diff-Quick (Dade) and the percentage of eozinophiles was determined by differential counting of at least 100 cells.



  Fluticasone and beclomethasone were used as standard substances under positive and negative control.



  The compounds were administered daily i. n. or i. p. in different doses 2 days before provocative test and up to the completion of the test.



  Compounds 8, 9 and 10 statistically significantly (t-test,   p < 0.    05) reduced the number of   eosinophiles    in the lung rinse with regard to the positive control. 



  Influence of compounds on the thymus weight
Male Sprague Dawley rats with a body weight of 200 g were randomly divided into groups of six animals. To anaesthetized animals sterilized weighed pellets of filter paper were implanted s. c. dorsally. The pellets in the control group were impregnated with acetone, whereas in the test groups they were impregnated either with the standard (prednisolone, Sigma) or with the compound 10. After 7 days the animals were put to sleep and their thymuses were isolated and weighed. The systemic effects were estimated by comparing the thymus weight in the test and control groups.



  The standard statistically significantly reduced the thymus weights with regard to the control, while the compound 10 did not affect the thymus weights. 



  Preparation processes with Examples
The present invention is illustrated but in no way limited by the following Examples.



  Example 1
Intermediate Mil, wherein   R4    represents a cladinose group   (9-deoxo-9a-aza-9a-(X-      aminopropyl)-9a-homoervthromycinA)   
To a solution   of 9-deoXo-9a-aza-9a-(ss-cianoethyl)-9a-homoerythromycin    A (3 g; 3.8 mmole) in ethanol (100 ml),   500 mg of PtO2    were added. The reaction was performed in an autoclave during 2 days under the pressure of 40 bar. Subsequently, the reaction mixture was filtered and ethanol was evaporated on a rotary evaporator. The residue was purified on a silica gel column (eluant: CH30H :   CH2Cl2      : NH4OH    = 50: 30: 2). 700 mg of the pure product were obtained.

   MS   (ES+)    : 793   (MH+)   
Intermediate Mil, wherein   R4    represents a hydroxyl group
The intermediate M11 was prepared according to the process descibed in Example 1 from 3-decladinosyl-9-deoxo-9a-aza-9a   (P-cianoethyl)-9a-homoerythromycin    A (3.5 g; 5.55 mmole).   985    mg of the product were obtained.

   MS   (ES+)    : 635 (MH+)
Example 2
Intermediate   M7,    wherein R4 represents a cladinose group
To a solution of   5-bromovaleric    acid (1.282 g; 7.07 mmole) in dry   CH2Cl2    (10   ml),      1    ml (7.23 mmole) of triethylamine, 868 mg (7.10 mmole) of 4-dimethylaminopyridine and 0.940 ml (7.63 mmole) of pivaloyl chloride were added. The solution was stirred for 2 hours at room temperature in a flow of argon and then a solution of azithromycin (2 g; 2.67 mmole) in 10 ml of dry   CH2CI2    was added. The reaction mixture was stirred for three days at room temperature. Subsequently, 60   ml    of saturated NaHCO3 solution were added to the reaction mixture and the layers were separated.

   The aqueous layer was twice more extracted with 40 ml of   CH2Cl2.    The combined organic extracts were washed with a saturated NaCl solution, dried over   K2CO3    and evaporated in a rotary evaporator. The obtained oily product was purified on a silica gel column (eluant: CH2Cl2 : CH30H : NH4,OH = 90: 9: 1.5). 511 mg of the pure product were obtained. MS   (ES+)    : 912   (MH+)   
The intermediates M7 and M9 were prepared according to the process described in
Example 2.



  Intermediate M7, wherein R4 represents a hydroxyl group.



  The intermediate M7 was prepared from 3-decladynosyl azithromycin   (1    g; 1.71 mmole) and 5-bromovaleric acid (929 mg; 5.13 mmole). 400 mg of the product were obtained. MS   (ES+)    : 754   (MH+)   
Intermediate M9
The intermediate M9 was prepared from 2'-acetyl-3-decladynosyl azithromycin (1.1 g; 1.70 mmole) and 5-bromovaleric acid   (921    mg; 5.09 mmole). 329 mg of the product were obtained.

   MS   (ES+)    : 795   (MH+)   
Example 3
Compound 1
To a suspension of   9cc-chloro-6a-fluoro-1li, l7a-dihydroxy-16a-methyl-3-    oxoandrosta-1, 4-diene-17ss-carboxylic acid (100 mg; 0.29 mmole) in dry   CH2Cl2    (5 ml) cooled to 0 C under argon, 0.380 ml (2.73 mmole) of triethylamine, 80 mg (0.59 mmole) of   1-hydroxybenzotriazole,    230 mg (0.29 mmole) of   9-deoxo-9a-aza-9a- (y-    aminopropyl)-9a-homoerythromycin A and 235 mg (1.23 mmole) of   1- (3-    dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride were added. The reaction mixture was stirred for 24 hours at room temperature in a flow of argon, then evaporated to a smaller volume on a rotary evaporator and purified on a silica gel column.

   (eluant:   CHCl3    : CH30H: NH40H = 6: 1: 0.1). 224 mg of white crystals were obtained (Table 1).



  Compounds 2-12 were prepared from   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-    homoerythromycin A and the corresponding steroid acids according to the process described in Example 3 and stated in Table 1.



  Compound 2
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (230 mg; 0.29 mmole) and   11ss,17&alpha;-dihydroxyandrosta-1,4-diene-3-one-17ss-carboxylic    acid (100 mg; 0.29 mmole), white crystals (285 mg) were obtained.



  Compound 3
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (197 mg; 0.25 mmole) and   llp-hydroxy-17a-metoxyandrost-4-ene-3-one-17 (3-carboxylic    acid (90 mg; 0.25 mmole), white crystals (115 mg) were obtained.



  Compound 4
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (174 mg; 0.22 mmole) and   9&alpha;-fluoro-11ss-hydroxy-16&alpha;-methyl-androsta-1,   4-diene-3-one17p-carboxylic acid (80 mg; 0.22 mmole), white crystals (224 mg) were obtained.



  Compound 5
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (230 mg; 0.29 mmole) and   llp-hydroxyandrost-4-ene-3-one-17p-carboxylic    acid (96 mg; 0.29 mmole), white crystals   (238    mg) were obtained.



  Compound 6 
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (230 mg; 0.29 mmole) and   9a-fluoro-1I3, 17a-dihydroxyandrosta-1, 4-diene-3-one-17p-    carboxylic acid (106 mg; 0.29 mmole), white crystals (225 mg) were obtained.



  Compound 7
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (230 mg; 0.29 mmole) and   6a-fluoro-llp, l7a-dihydroxy-16a-methyl-androsta-1, 4-diene-      3-one-17 (3-carboxylic    acid (110 mg; 0.29 mmole), white crystals (107 mg) were obtained.



  Compound 8
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (230 mg; 0.29 mmole) and   llss, 17a-dihydroxyandrost-4-ene-3-one-17ss-carboxylic    acid (100 mg; 0.29 mmole), white crystals (75 mg) were obtained.



  Compound 9
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (230 mg; 0.29 mmole) and   6a,      9a-difluoro-11 (3, 17a-dihydroxy-16a-methylandrosta-1,    4  diene-3-one-17ss-carboxylic    acid (115 mg; 0.29 mmole), white crystals (258 mg) were obtained.



  Compound 10
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (230 mg; 0.29 mmole) and   9&alpha;-fluoro-11ss17&alpha;-dihydroxy-16&alpha;-methylandrosta-1,   4-diene-3  one-17ss-carboxylic    acid (110 mg; 0.29 mmole), white crystals (224 mg) were obtained.



  Compound 11 
By a reaction of   9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin    A (197 mg; 0.24 mmole) and   9cx-chloro-llss, 17cc-dihydroxy-16a-methylandrosta-1,    4-diene-3  one-17 (3-carboxylic    acid (96 mg; 0.24 mmole), white crystals (170 mg) were obtained.



  Compound 12
By a reaction of 9-deoxo-9a-aza-9a- (Y-aminopropyl)-9a-homoerythromycin A (230 mg; 0.29 mmole) and   17a-hydroxyandrost-4-ene-3,      11-dione-17ss-carboxylic    acid (100 mg; 0.29 mmole), white crystals (247 mg) were obtained.



  Example 4
Compound 13
A mixture of 6a,   9a-difluoro-llp, 17a-trihydroxy-3-oxoandrosta-1, 4-diene-17p-    carboxylic acid-16,17-acetonide (104 mg; 0.24 mmole), diizopropylethylamine (45 ml, 0.26 mmole), 1-hidroxybenzotriazole (65 mg; 0.48 mmole),   9-deoxo-9a-aza-9a- (y-    aminopropyl)-9a-homoerythromycin A (190 mg ; 0.24 mmole) and 1- (3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (184 mg; 0.96 mmole) in dry DMF (10 ml) was heated under reflux while stirring at   100  C    in an argon atmosphere.



  Subsequently, the reaction mixture was cooled and evaporated on a rotary evaporator.



  The residue was purified on a silica gel column (eluant :   CHC13 : CH30H : NH40H    6: 1: 0.1). 31 mg of the pure product were obtained (Table 1).



  Compound 14
Compound 14 was prepared according to the process described in Example 4 from   6a, 9&alpha;-difluoro-11ss,16&alpha;, 17&alpha;-trihydroxy-3-oxoandrosta-1,4-diene-17ss-carboxylic      acid-16,    17-acetonide (104 mg; 0.24 mmole) and   3-decladinosyl-9-deoxo-9a-aza-9a- (Y-    aminopropyl)-9a-homoerythromycin A (150 mg; 0,24 mmole). 60 mg of the product were obtained (Table 1). 



  Example 5
Compound 15
To a suspension of   9&alpha;-chloro-6&alpha;-fluoro-11ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-    oxoandrosta-1,   4-diene-17p-carboxylic    acid (110 mg; 0.27 mmole) in dry   CH2C12    (5 ml) cooled to   0  C    in a flow of argon, 0.348 ml (2.5 mmole) of triethylamine, 73 mg (0.54 mmole) of 1-hydroxybenzotriazole, 169 mg (0.27 mmole) of 3-decladinosyl-9  deoxo-9a-aza-9a- (- (y-aminopropyl)-9a-homoerythromycin    A and 215 mg (1.12 mmole) of   1- (3-dimethylaminopropyl)-3-ethyl-carbodiimide    hydrochloride were added.

   The reaction mixture was stirred for 24 hours at room temperature, evaporated to a smaller volume on a rotary evaporator and purified on a silica gel column (eluant:
CHC13 : CH30H: NH40H= 6: 1: 0.1).   235    mg of white crystals were obtained (Table 1).



  Compounds 16-19 were prepared according to the process described in Example 5 and stated in Table 1.



  Compound 16
By a reaction of 6a-fluoro-llp, 17a-dihydroxy-16a-methyl-3-oxoandrosta-1, 4-diene17i-carboxylic acid (90 mg; 0.24 mmole) and   3-decladinosyl-9-deoxo-9a-aza-9a- (- (Y-    aminopropyl)-9a-homoerythromycin A (150 mg; 0.24 mmole), white crystals (138 mg) were obtained.



  Compound 17
By a reaction   of 6a, 9ct-difluoro-llss, 17ct-dihydroxy-16cc-methyl-3-oXoandrosta-1,    4  diene-17p-carboxylic    acid (94 mg; 0.24 mmole) and 3-decladinosyl-9-deoxo-9a-aza  9a- (- (y-aminopropyl)-9a-homoerythromycin    A (150   mg ;    0.24 mmole), white crystals (163   mg)    were obtained.



  Compound 18 
By a reaction of   llss, 17u-dihydroxyandrost-4-ene-3-one-17ss-carboxylic    acid (84 mg; 0.24 mmole) and   3-decladinosyl-9-deoxo-9a-aza-9a- (- (y-aminopropyl)-9a-homo-    erythromycin A (150 mg; 0.24 mmole), white crystals (112 mg) were obtained.



  Compound 19
By a reaction   of 9a-fluoro-1li, 17a-dihydroxy-16a-methyl-3-oxoandrosta-1,    4-diene17p-carboxylic acid (110 mg; 0.29 mmole) and 3-decladinosyl-9-deoxo-9a-aza-9a- ( (y-aminopropyl)-9a-homoerythromycin A (185 mg; 0.29 mmole), white crystals (155 mg) were obtained.



  Example 6
Compound 20
To a suspension of stereoisomeric acid (20 R,   S)-11 P,    17,20-trihydroxy-3-oxoandrosta  1,      4-diene-21-carboxylic    acid (200 mg; 0.53 mmole) in dry   CH2Cl2    (5 ml) under argon, 0.760 ml of triethylamine, 160 mg (1.2 mmole) of   1-hydroxybenzotriazole,    460 mg (0.58 mmole) of 9-deoxo-9a-aza-9a- (y-aminopropyl)-9a-homoerythromycin A and 470 mg (2.45 mmole) of   1- (3-dimethylaminopropyl)-3-ethyl-carbodiimide    hydrochloride were added.

   The reaction mixture was stirred for 24 hours at room temperature, then evaporated to a smaller volume on a rotary evaporator and purified on a silica gel column (eluant:   CHCl3    : CH30H: NH40H   =    6: 1: 0.1). 405 mg of the product were obtained (Table 1).



  Example 7
Compound 21
To a solution   of 9&alpha;-fluoro-11ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-,    4-diene17p-carboxylic acid (135 mg; 0.35 mmole) in dry DMF (3 ml), potassium carbonate (49 mg; 0.35 mmole) was added. The reaction mixture was stirred at   0 C    in a flow of argon and then a solution of 311 mg (0.39 mmole) of the intermediate M9 in 4 ml of dry DMF was added. After stirring for 5 days at room temperature, DMF was evaporated on a rotary evaporator and the residue was purified on a silica gel column (eluant:   CHCl3    : CH30H:   NH40H    =10: 1: 0.1). 53 mg of the pure product were obtained (Table 1).



  Example 8
Compound 22
To a solution   of 6a, 9a-difluoro-11 3, 17a-dihydroxy-16a-methyl-3-oxoandrosta-1,    4  diene-17 (3-carboxylic    acid (100 mg; 0.25 mmole) in dry DMF (3 ml), potassium carbonate (35 mg; 0.25 mmole) was added. The reaction mixture was stirred at   0 C    in a flow of argon and then a solution of 252 mg (0.28 mmole) of the intermediate M7, wherein R4 represents cladinose, in 4 ml of dry DMF was added. After stirring for 2 days at room temperature, DMF was evaporated on a rotary evaporator and the residue was purified on a silica gel column (eluant:   CHCl3    : CH30H:   NH40H    = 12: 1: 0.1). 42 mg of the pure product were obtained (Table 1).



  Compounds 23 and 24 were prepared according to the process described in Example 8 and stated in Table   1.   



  Compound 23
By a reaction   of 9a-fluoro-lli, l7a-dihydroxy-16a-methyl-3-oxoandrosta-1,    4-diene  177i-carboxylic    acid (99 mg; 0.26 mmole) and 285 mg (0.31 mmole) of intermediate
M7, wherein R4 represents cladinose, white crystals (42 mg) were obtained.



  Compound 24
By a reaction   of 9a-chloro-6a-fluoro-1l, 17a-dihydroxy-16a-methyl-3-oxoandrosta-      1,      4-diene-17p-carboxylic    acid (81 mg; 0.20 mmole) and 222 mg (0.24 mmole) of intermediate M7, wherein   R4    represents cladinose, white crystals (54 mg) were obtained (Table 1). 



  Example 9
Compound 25
To a solution   of 9ct-fluoro-11 ss, 17cc-dihydroxy-16cc-methyl-3-oxoandrosta-1,    4-diene  177i-carboxylic    acid   (83    mg; 0.22 mmole) in dry DMF (3 ml), potassium carbonate (30 mg; 0.22 mmole) was added. The reaction mixture was stirred at   0 C    in a flow of argon and then a solution of 182 mg (0.24 mmole) of intermediate M7, wherein   R4    represents a hydroxyl group, in 4 ml of dry DMF was added. After stirring for 24 hours at room temperature, DMF was evaporated on a rotary evaporator and the residue was purified on a silica gel column (eluant:   CHC13 : CH30H : NH40H    10: 1: 0.1). 57 mg of the pure product were obtained.



  Compounds 26 and 27 were prepared according to the process described in Example 9 and stated in Table   1.   



  Compound 26
By a reaction   of 6&alpha;-fluoro-11ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-1,   4-diene17i-carboxylic acid (85 mg; 0.22 mmole) and 225 mg (0.25 mmole) of intermediate
M7, wherein   R4    represents a hydroxyl group, white crystals (20 mg) were obtained.



  Compound 27
By a reaction   of 9a-chloro-6a-fluoro-lli, l7a-dihydroxy-16a-methyl-3-oxoandrosta-      1,      4-diene-17p-carboxylic    acid (100 mg; 0.24 mmole) and 200 mg (0.26 mmole) of intermediate M7, wherein   R4    represents a hydroxyl group, white crystals (59 mg) were obtained.



  Example 10
Compound 28 
To a solution   of 9&alpha;-fluoro-11ss,17&alpha;-dihydroxy-16&alpha;-methyl-3-oxoandrosta-1,    4-diene17p-carboxylic acid (80 mg; 0.21 mmole) in dry DMF (3 ml), potassium carbonate (30 mg; 0.21 mmole) was added. The reaction mixture was stirred for one hour at room temperature in a flow of argon and then a solution of 163 mg (0.23 mmole) of 3-O  decladinosyl-6-O-methyl-3-oxoerythromycin-9-0-   (2-bromoethyl) oxime in 3 ml of dry
DMF was added. The reaction mixture was heated for 4 hours at   100  C.    Then it was cooled to room temperature and 40 ml of ethyl-acetate and water   (1    :   1)    were added.



  The organic layer was separated, washed with water and dried over anhydrous potassium carbonate. The residue was purified on a silica gel column with a solvent system chlorophorm : methanol: ammonia = 10: 1: 0.1.160 mg of white crystals were obtained (Table 1).



  Table 1
EMI39.1     


<tb> Comp. <SEP> Structure <SEP> Molecular <SEP> formula <SEP> M. <SEP> p. <SEP> ( C)
<tb>  <SEP> (ES)
<tb>  <SEP> C6, <SEP> HIOICIFN3016 <SEP> 194-202 <SEP> 1187
<tb>  <SEP> Ho
<tb>  <SEP> ., <SEP> HtoX <SEP> çOH
<tb>  <SEP> NH <SEP> C
<tb>  <SEP> HO <SEP> HH <SEP> OH <SEP> 0
<tb>  <SEP> CI,...
<tb>



   <SEP> O <SEP> i <SEP> \ <SEP> O. <SEP> \
<tb>  <SEP> 0
<tb>  <SEP> C60H101N316 <SEP> 1121
<tb>  <SEP> HCI.
<tb>



   <SEP> OH
<tb>  <SEP> oH,.. <SEP> O <SEP> ¯
<tb>  <SEP> ;'HO' <SEP> ('')
<tb>  <SEP> O <SEP> i, <SEP> O <SEP> "L <SEP> \
<tb>  <SEP> HO,
<tb>  <SEP> 'Ha <SEP> y
<tb>  <SEP> OH
<tb>  <SEP> H <SEP> OCH, <SEP> OH-""0
<tb>  <SEP> H <SEP> ¯..., <SEP> DH
<tb>  <SEP> 4 <SEP> i <SEP> O. <SEP> \.
<tb>



   <SEP> QNHL/'LPH)- 
<tb>  <SEP> NH <SEP> ¯/ <  <SEP>  > 
<tb>  <SEP> HO,-  <SEP> 0 <SEP> H
<tb>  <SEP> NH
<tb>  <SEP> NL 
<tb>  <SEP> Ho <SEP> 0
<tb>  <SEP> O/F <SEP> \ <SEP> o.
<tb>  
EMI40.1     





   <SEP> C60HlO3N3015 <SEP> 1106
<tb>  <SEP> HO-
<tb>  <SEP> 'HO <SEP> 
<tb>  <SEP> 'HO <SEP> ; <SEP> |
<tb>  <SEP> H <SEP> I...
<tb>



   <SEP> OH
<tb>  <SEP> po
<tb>  <SEP> 6 <SEP> N <SEP> CE3oHlooFN3016 <SEP> 1139
<tb>  <SEP> . <SEP> HCf
<tb>  <SEP> cl <SEP> cl
<tb>  <SEP> OH'O <SEP> 
<tb>  <SEP> 0 <SEP> 0-1
<tb>  <SEP> OH
<tb>  <SEP> OH
<tb>  <SEP> 0
<tb>  <SEP> 7 <SEP> C61H, <SEP> 02FN3016 <SEP> 175-178 <SEP> 1153
<tb>  <SEP> H <SEP> OH <SEP> Qt
<tb>  <SEP> X <SEP> \ <SEP> 00
<tb>  <SEP> Ouzo
<tb>  <SEP> J-J <SEP> HO-O
<tb>  <SEP> i <SEP> i
<tb>  <SEP> O <SEP> i <SEP> 1 <SEP> O, <SEP> O
<tb>  <SEP> . <SEP> 0 <SEP> 0
<tb>  <SEP> 8 <SEP> C60HI03N3016 <SEP> 144 <SEP> 1123
<tb>  <SEP> H <SEP> (I
<tb>  <SEP> 'OH
<tb>  <SEP> H <SEP> oN. <SEP> O.
<tb>



   <SEP> OH
<tb>  <SEP> OH
<tb>  <SEP> uN <SEP> C61 <SEP> H101F2N3016 <SEP> 169 <SEP> 1171
<tb>  <SEP> hui
<tb>  <SEP> Oh <SEP> O
<tb>  <SEP> OH <SEP> o
<tb>  <SEP> N < tHoOH <SEP> W) <SEP> 
<tb>  <SEP> HO <SEP> I"CH <SEP> 0, <SEP> H
<tb>  <SEP> i <SEP> \'w¯L
<tb>  <SEP> C)
<tb>  <SEP> F
<tb>  <SEP> 10-N <SEP> C61H, <SEP> 02FN3016 <SEP> 170-175 <SEP> 1153
<tb>  <SEP> . <SEP> Hd'
<tb>  <SEP> Ho <SEP> 0
<tb>  <SEP> ' <SEP> O <SEP> W
<tb>  <SEP> H
<tb> 0'JN. <SEP> CeiHiozFCie'T7 <SEP> (M75'H53
<tb>  <SEP> . <SEP> ¯¯, <SEP> oH <SEP> o <SEP> o,
<tb>  <SEP> OH
<tb>  <SEP> i <SEP> F <SEP> O
<tb>  <SEP> HA.
<tb>



   <SEP> C6, <SEP> H, <SEP> 02CIN3016 <SEP> 1169
<tb>  <SEP> "'HO'W
<tb>  <SEP> 0 
<tb>  <SEP> :
<tb>  <SEP> I <SEP>  <  <SEP> OnOH
<tb>  <SEP> I
<tb>  <SEP> HC) <SEP> 
<tb>  <SEP> OH
<tb>  
EMI41.1     


<tb> 12  <SEP> 12 <SEP> COHIOIN3016 <SEP> 1121
<tb>  <SEP> zuNH
<tb>  <SEP> 0 <SEP> OH <SEP> OH
<tb>  <SEP> où <SEP> OH
<tb>  <SEP> 3
<tb> 13
<tb>  <SEP> 13 <SEP> 14 <SEP> C63HlO3F2N3017 <SEP> 178 <SEP> 1212
<tb>  <SEP> i
<tb>  <SEP> :'Hc"
<tb>  <SEP> OH <SEP> O'
<tb>  <SEP> OH <SEP> ... <SEP> O
<tb>  <SEP> HO,."o <SEP> OH
<tb>  <SEP> 0- <SEP> \ <SEP> OH
<tb>  <SEP> Cl\
<tb>  <SEP> 0 <SEP> 0
<tb>  <SEP> 0
<tb>  <SEP> y
<tb> 14 <SEP> 8, <SEP> C55H89F2N3014-1055
<tb>  <SEP> Ho
<tb>  <SEP> 1¯, <SEP> Ht' > 
<tb>  <SEP> oH <SEP> w <SEP>  
<tb>  <SEP> Ho
<tb>  <SEP> AW <SEP> oK
<tb>  <SEP> o <SEP> ¯.
<tb>



   <SEP> 0 <SEP> 0
<tb>  <SEP> 0 <SEP> 0
<tb>  <SEP> F
<tb> 15 <SEP> C53H87CIFN3013 <SEP> 130-132 <SEP> 1086
<tb>  <SEP> NH <SEP> WoH <SEP> ss
<tb>  <SEP> HX <SEP> oH <SEP> H
<tb>  <SEP> H <SEP> I <SEP> OH
<tb>  <SEP> H'IOH <SEP> OH
<tb>  <SEP> H
<tb>  <SEP> CL
<tb>  <SEP> ci
<tb>  <SEP> 16 <SEP> C53HBBFN3013 <SEP> 202-204 <SEP> 995
<tb>  <SEP> N
<tb>  <SEP> N
<tb>  <SEP> OH'
<tb>  <SEP> Ho., <SEP> pHH. <SEP> ,,
<tb>  <SEP> i
<tb>  <SEP> p <SEP> \ <SEP> O
<tb>  <SEP> F
<tb> 17 <SEP> I <SEP> C53H87F2N3 13 <SEP> 182 <SEP> 1013
<tb>  <SEP> N
<tb>  <SEP> ' <SEP> OU <SEP> zoo
<tb>  <SEP> oh'
<tb>  <SEP> HO <SEP> wOHH., <SEP> ow <SEP> ". <SEP> pH
<tb>  <SEP> H
<tb>  <SEP> ozon
<tb>  <SEP> p <SEP> 1 <SEP> .,
<tb>  <SEP> F
<tb>  
EMI42.1     


<tb> 18 <SEP> C52H89N3013 <SEP> 160-161 <SEP> 965
<tb>  <SEP> HO'
<tb>  <SEP> NH <SEP> :

   <SEP> pH <SEP> ?... <SEP> p
<tb>  <SEP> ,.. <SEP> p
<tb>  <SEP> H <SEP> oh
<tb>  <SEP> . <SEP> oh
<tb>  <SEP> 0 <SEP> O
<tb> 19 <SEP> sl <SEP> C53H8BFN3 13 <SEP> 260-265 <SEP> 995
<tb>  <SEP> Hd,
<tb>  <SEP> /'. <SEP> oHt
<tb>  <SEP> Nu
<tb>  <SEP> OH <SEP> .. <SEP> 0
<tb>  <SEP> H'O1HH
<tb>  <SEP> H <SEP> 1.
<tb>



   <SEP> /F <SEP> OH <SEP> 1
<tb>  <SEP> O <SEP> O
<tb>  <SEP> 20 <SEP> C61H, <SEP> 03N3017 <SEP> 1151
<tb>  <SEP> 'Hpn. <SEP> 
<tb>



   <SEP> NU
<tb>  <SEP> HOHOH"'
<tb>  <SEP> HO-,, <SEP> IOH <SEP> OH
<tb>  <SEP> yX",)
<tb>  <SEP> 0 <SEP> 4 <SEP> \.
<tb>



   <SEP> O
<tb> 21 <SEP> C58H <SEP> 93F <SEP> N20 <SEP> 16 <SEP> 174-175 <SEP> 1094
<tb>  <SEP> ' <SEP> N
<tb>  <SEP> ¯ <SEP> H,.,.
<tb>



   <SEP> OH > o
<tb>  <SEP> ss <SEP> ss <SEP> oH
<tb>  <SEP> H'IOH
<tb>  <SEP> O
<tb>  <SEP> O <SEP> 
<tb>  <SEP> u
<tb>  <SEP> H <SEP> lot
<tb>  <SEP> w.,
<tb>  <SEP> 6
<tb>  <SEP> O
<tb> 22 <SEP> iN, <SEP> , <SEP> / <SEP> oH <SEP> C64H104F2N218 <SEP> I59-I60 <SEP> I228
<tb>  <SEP> OH--"
<tb>  <SEP> 0
<tb>  <SEP> HO.. <SEP> OH <SEP> ¯N <SEP> OH.
<tb>



   <SEP> 0
<tb>  <SEP> O
<tb>  <SEP> F <SEP> H
<tb>  <SEP> F
<tb> 23 <SEP> C64H, <SEP> 05FN2018 <SEP> 161-168 <SEP> 1210
<tb>  <SEP> OH
<tb>  <SEP> zou
<tb>  <SEP> J^ <SEP> o <SEP> Q <SEP> y, <SEP>  ¯
<tb>  <SEP> /', <SEP> OH <SEP> D
<tb>  <SEP> zozo
<tb>  <SEP> w <SEP> Q
<tb>  <SEP> H <SEP> IOH-N <SEP> OH'
<tb>  <SEP> Hdf <SEP> a
<tb>  <SEP> O
<tb>  
EMI43.1     


<tb> 24 <SEP> C <SEP> H <SEP> CIF <SEP> N <SEP> 91-99 <SEP> 1244
<tb>  <SEP> N., <SEP> oH <SEP> 64 <SEP> 104 <SEP> 2 <SEP> 18
<tb>  <SEP> d <SEP> O <SEP> ..,
<tb>  <SEP> oh
<tb>  <SEP> o, <SEP> ¯i <SEP> I.. <SEP> oH,
<tb>  <SEP> 0
<tb>  <SEP> zu
<tb>  <SEP> H. <SEP> pH.... <SEP> N <SEP> OH. <SEP> '
<tb>  <SEP> H'-'1 <SEP> .
<tb>



   <SEP> Cul
<tb>  <SEP> O
<tb>  <SEP> H-0
<tb>  <SEP> C <SEP> H <SEP> FN <SEP> 0 <SEP> o <SEP> los2
<tb>  <SEP> 56 <SEP> 91 <SEP> 2 <SEP> 15
<tb>  <SEP> iN <SEP> O
<tb>  <SEP> O
<tb>  <SEP> . <SEP> o <SEP> H
<tb>  <SEP> 0
<tb>  <SEP> H <SEP> IOH <SEP> t. <SEP> oH: <SEP> 
<tb>  <SEP> . <SEP> HO
<tb>  <SEP> 0
<tb>  <SEP> /F
<tb>  <SEP> O
<tb> 26 <SEP> C <SEP> H <SEP> F <SEP> N <SEP> 0 <SEP> 145-152 <SEP> 1052
<tb>  <SEP> 56 <SEP> 91 <SEP> 2 <SEP> 15
<tb>  <SEP> ¯ < 
<tb>  <SEP> Wiw
<tb>  <SEP> H.,
<tb>  <SEP> 0 <SEP> oh
<tb>  <SEP> H <SEP> 0"'OH-N <SEP> OH,-"
<tb>  <SEP> ,'/¯"O
<tb>  <SEP> HO
<tb>  <SEP> O.
<tb>



   <SEP> 27Cg6H9oC) <SEP> FN20i5130-132086
<tb>  <SEP> '\05
<tb>  <SEP> OH
<tb>  <SEP> of, <SEP> OH
<tb>  <SEP> O
<tb>  <SEP> - <SEP> 0
<tb>  <SEP> IoH <SEP> N <SEP> oH <SEP> :'
<tb>  <SEP> o
<tb>  <SEP> o
<tb>  <SEP> cl
<tb>  <SEP> F
<tb>  <SEP> F
<tb> 28 <SEP> ... <SEP> N2015 <SEP> 1007
<tb>  <SEP> H
<tb>  <SEP> 28 <SEP> 3
<tb>  <SEP> 0 <SEP> oit
<tb>  <SEP> H <SEP> oh
<tb>  <SEP> rHr' <SEP> Hc 
<tb>  <SEP> HO <SEP> 0
<tb>

Claims

Claims 1. Compounds, their salts and solvates represented by the structure I EMI44.1 characterized in that M represents a macrolide subunit possessing the property of accumulation in inflammatory cells, A represents an anti-inflammatory subunit that can be steroid or nonsteroid and L represents a chain linking M and A, and improved therapeutic effect of these compounds in the treatment of inflammation diseases and conditions.
2. Compounds, their salts and solvates represented by the structure I EMI44.2 characterized in that M represents a macrolide subunit represented by the formulas EMI44.3 wherein Rl is hydrogen or a methyl group, R2 and R3 are both hydrogen or together form a bond, or R2 is an amino group represented by the substructure -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen, R4 is a hydroxyl or cladinosyl group represented by the structure EMI45.1 R4 and Rs may also together form a carbonyl group, with the proviso that Ri is then a methyl group,
EMI45.2 wherein Rl is hydrogen or a methyl group, R2 and R3 are both hydrogen or together form a bond or R2 is an amino group represented by the substructur -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen, R4 may be any alkyl group having 1-4 carbon atoms, preferably a methyl group;
EMI46.1 wherein Ri is hydrogen or a methyl group, R2 and R3 are both hydrogen or together form a bond or R2 is an amino group represented by the substructur -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen, R4 is a hydroxyl or cladinosyl group represented by the structure EMI46.2 R4 and R5 may also together form a carbonyl group, with the proviso that Ri is then a methyl group, EMI47.1 wherein Rl is hydrogen or a methyl group, R2 and R3 are both hydrogen or together form a bond or R2 is an amino group represented by the substructure - NR'R" wherein R'and R"may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms,
with the proviso that R3 is then hydrogen, R4 is a hydroxyl or cladinosyl group represented by the structure EMI47.2 wherein RI is hydrogen or a methyl group, R2 and R3 are both hydrogen or together form a bond, or R2 is an amino group represented by the substructur -NR'R'' wherein R' and R'' may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen, R4 is hydroxyl or cladinosyl group represented by the structure:
EMI48.1 R5 may be any alkyl group having 1-4 carbon atoms, preferably a methyl group, EMI48.2 wherein Rl is hydrogen or an acetyl group, R2 and R3 are both hydrogen or together form a bond, or R2 is an amino group represented by the substructur -NR'R'' wherein R'and R"may be, independently from each other, hydrogen or any alkyl or cycloalkyl group having 1-6 carbon atoms, with the proviso that R3 is then hydrogen, R4 is a hydroxyl or cladinosyl group represented by the structure EMI49.1 R5 may be any alkyl group having 1-4 carbon atoms, preferably a methyl group, and A represents an anti-inflamatory subunit represented by the formulas :
EMI49.2 wherein Z represents oxygen or NH group, Ri is hydrogen or hydroxyl or O-acyl or Oalkyl group, R2 represents hydrogen or a methyl group, which may be oriented in a-or ss-position, X, is hydrogen or halogen, X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine, 1,2-position may represent a double or single carbon-carbon bond, EMI50.1 wherein Z represents oxygen or a NH group, R, is hydrogen or a hydroxyl or O-acyl or 0-alkyl group, R2 represents hydrogen or an acyl group, Xi is hydrogen or halogen, X2 is hydrogen or halogen, whereat halogen represents fluorine, chlorine or bromine, EMI50.2 or stereoisomeric forms thereof, wherein the 1,2-position represents a saturated or unsaturated double bond,
wherein Z represents oxygen or NH group, Rl represents hydrogen, a straight or branched hydrocarbon chain having 1-4 carbon atoms, R2 represents hydrogen, a straight or branched hydrocarbon chain having 1-10 carbon atoms, with the proviso that R, and R2 are not simultaneously hydrogen Xi is hydrogen or halogen, X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine;
EMI51.1 or stereoisomeric forms thereof, wherein the 1,2-position represents a saturated or unsaturated double bond, wherein Z represents oxygen or a NH group, Ri represents hydrogen, a straight or branched hydrocarbon chain having 1-4 carbon atoms, R2 represents hydrogen, a straight or branched hydrocarbon chain having 1-10 carbon atoms, with the proviso that Ri and R2 are not simultaneously hydrogen, Xi is hydrogen or halogen, X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine;
EMI51.2 or stereoisomeric forms thereof, wherein the 1,2-position represents a saturated or unsaturated double bond, Rl represents hydrogen, a straight or branched hydrocarbon chain having 1-4 carbon atoms, R2 represents hydrogen, a straight or branched hydrocarbon chain having 1-10 carbon atoms, with the proviso that Rl and R2 are not simultaneously hydrogen, Xi is hydrogen or halogen, X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine;
EMI52.1 wherein Z represents oxygen or a NH group, Rl is hydrogen or a hydroxyl group with a free hydrogen or a hydroxyl group or O-acyl or 0-alkyl group, R2 represents hydrogen or a methyl group, which may be oriented in a-or p-position, R3 represents hydrogen or a radical of an acid having 1-4 carbon atoms, Xi is hydrogen or halogen, X2 is hydrogen or halogen, with halogen meaning fluorine, chlorine or bromine, 1,2-position may represents double or single carbon-carbon bond, and L represents a chain with the formula -(CR3R4) nCR5R6-, wherein Ri, R2, R3, R4, R5, R6 may be hydrogen, C1-C4 alkyl, aryl, metoxy, halogen, hydroxy or mercapto groups, wherein n is 1-10, and one or more-CR3R4-groups may be substituted with oxygen, sulphur,
an aromatic nucleus or an amino group additionally bearing hydrogen or a C1-C4 alkyl or aryl group with the proviso that at least one methylene group is situated at the end of the linking L group.
3. Compound and salt according to claims 1 and 2, characterized in that the macrolide subunit M from structure I is represented by the general structure M1, wherein Rl is a methyl group, R2 is a dimethylamino group, with the proviso that R3 is then hydrogen, R4 is cladinose, R4 and R5 may also together form a carbonyl group, and the steroid subunit of the structure I is represented by one of the structures Al to A4 and A6, wherein Al is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Rl is a hydroxyl group which can have a free hydrogen or is additionally alkylated with an alkyl group R'having 1-4 carbon atoms, preferably a methyl group, R2 is hydrogen or a methyl group, Xl is hydrogen or fluorine, X2 is hydrogen,
wherein A2 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Rl is hydrogen, R2 is hydrogen, Xi is fluorine, X2 is hydrogen, wherein A3 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, R, and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A4 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Rl and R2 are methyl groups, Xi is fluorine, X2 isfluorine, wherein A6 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is a double carbon-carbon bond, Ri is a hydroxyl group, R2 is hydrogen or a methyl group in a-or ss-position, preferably in a-position, R3 is hydrogen,
Xi is hydrogen, fluorine or chlorine, X2 is hydrogen or fluorine, wherein chain L is indicated as defined in claim 2, wherein Rl to R4 are hydrogen and n is 1-10.
4. Compound and salt according to claims 1 and 2, characterized in that the macrolide subunit M from the structure I is represented by the general structure M2, wherein Rl is hydrogen, R2 is a dimethylamino group, with the proviso that R3 is then hydrogen, R4 is a methyl group, and the steroid subunit from the structure I is represented by one of the structures Al to A4 and A6, wherein Al is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Rl is hydroxyl group, which can have a free hydrogen or is additionally alkylated with alkyl group R'having 1-4 carbon atoms, preferably methyl group, R2 is hydrogen or methyl group, Xi is hydrogen or fluorine, X2 is hydrogen, wherein A2 is defined as in claims 1 and 2 wherein Z represents oxygen or a NH group,
Rl is hydrogen, R2 is hydrogen, Xi is fluorine, X2 is hydrogen, wherein A3 is defined as in claims 1 and 2 wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Rl and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A4 is defined as in claims 1 and 2 wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Rl and R2 are methyl groups, Xl is fluorine, X2 is fluorine, wherein A6 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is double carbon-carbon bond, Rl is hydroxyl group, R2 is hydrogen or methyl group in a-or ss-position, preferably in a-position, R3 is hydrogen, Xi is hydrogen,
fluorine or chlorine, X2 is hydrogen or fluorine, wherein chain L is indicated as defined in claim 2, wherein Rl to R4 are hydrogen and n is 1-10.
5. Compound and salt according to claims 1 and 2, characterized in that the macrolide subunit M of the structure I is represented by the general structure M3, wherein Rl is hydrogen, R2 is dimethylamino group, with the proviso that R3 is then hydrogen, R4 and R5 may together form carbonyl group, and steroid subunit of the structure I is indicated with one of the structures Al to A4 and A6, wherein Al is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Rl is hydroxyl group which can have a free hydrogen or is additionally alkylated with alkyl group R'having 1-4 carbon atoms, preferably methyl group, R2 is hydrogen or methyl group, Xi is hydrogen or fluorine, X2 is hydrogen, wherein A2 is defined as in claims 1 and 2,
wherein Z represents oxygen or a NH group, Rl is hydrogen, R2 is hydrogen, Xl is fluorine, X2 ishydrogen, wherein A3 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Ri and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A4 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Ri and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A6 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is a double carbon-carbon bond, Rl is a hydroxyl group, R2 is hydrogen or a methyl group in a-or {3-position, preferably in a-position, R3 is hydrogen, Xi is hydrogen, fluorine or chlorine,
X2 is hydrogen or fluorine, wherein chain L is indicated as defined in claim 2, wherein Rl to R4 are hydrogen and n is 1-10.
6. Compound and salt according to claims 1 and 2, characterized in that the macrolide subunit M of the structure I is represented by the general structure M4, wherein Rl is hydrogen, R2 is a dimethylamino group, with the proviso that R3 is then hydrogen, Rt is a cladinose or hydroxyl group, and the steroid subunit of the structure I is represented by one of the structures Al to A4 and A6, wherein Al is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Ri is a hydroxyl group, which can have a free hydrogen or is additionally alkylated with an alkyl group R'having 1-4 carbon atoms, preferably a methyl group, R2 is hydrogen or a methyl group, Xi is hydrogen or fluorine, X2 is hydrogen, wherein A2 is defined as in claims 1 and 2,
wherein Z represents oxygen or a NH group, Rl is hydrogen, R2 is hydrogen, Xi is fluorine, X2 is hydrogen, wherein A3 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Rl and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A4 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Rl and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A6 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is a double carbon-carbon bond, Rl is a hydroxyl group, R2 is hydrogen or a methyl group in a-or (3-position, preferably in a-position, R3 is hydrogen, Xi is hydrogen, fluorine or chlorine,
X2 is hydrogen or fluorine, wherein chain L is indicated as defined in claim 2, wherein Rl to R4 are hydrogen and n is 2-10.
7. Compound and salt according to claims 1 and 2, characterized in that the macrolide subunit M of the structure I is represented by the general structure M5, wherein Rl is hydrogen, R2 is a dimethylamino group, with the proviso that R3 is then hydrogen, R4 is a cladinose or hydroxyl group, R5 is a methyl group, and the steroid subunit of the structure I is represented by one of the structures Al to A4 and A6, wherein Al is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Rl is a hydroxyl group, which can have a free hydrogen or is additionally alkylated with an alkyl group R'having 1-4 carbon atoms, preferably a methyl group, R2 is hydrogen or a methyl group, Xi is hydrogen or fluorine, X2 is hydrogen, wherein A2 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Ri is hydrogen,
R2 is hydrogen, Xi is fluorine, X2 is hydrogen, wherein A3 is defined as in claims 1 and 2 wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Ri and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A4 is defined as in claims 1 and 2 wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, Rl and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A6 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is a double carbon-carbon bond, Rl is a hydroxyl group, R2 is hydrogen or a methyl group in a-or ss-position, preferably in a-position, R3 is hydrogen, Xl is hydrogen, fluorine or chlorine, X2 is hydrogen or fluorine,
wherein chain L is indicated as defined in claim 2, wherein Rl to R4 are hydrogen and n is 2-10.
8. Compound and salt according to claims 1 and 2, characterized in that the macrolide subunit M of the structure I is represented by the general structure M6, wherein Ri is hydrogen, R2 is a dimethylamino group, with the proviso that R3 is then hydrogen, R4 is a cladinose or hydroxyl group, R5 is a methyl group, and the steroid subunit of the structure I is represented by one of the preferred structures Al to A4 and A6, wherein Al is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Rl is a hydroxyl group, which can have a free hydrogen or is additionally alkylated with an alkyl group R'having 1-4 carbon atoms, preferably a methyl group, R2 is hydrogen or a methyl group, Xi is hydrogen or fluorine, X2 is hydrogen, wherein A2 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, Rl is hydrogen, R2 is hydrogen,
Xt is fluorine, X2 is hydrogen, wherein A3 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is unsaturated, R, and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A4 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1, 2-position is unsaturated, Rl and R2 are methyl groups, Xi is fluorine, X2 is fluorine, wherein A6 is defined as in claims 1 and 2, wherein Z represents oxygen or a NH group, 1,2-position is a double carbon-carbon bond, Rl is a hydroxyl group, R2 is hydrogen or a methyl group in a-or p-position, preferably in a-position, R3 is hydrogen, Xi is hydrogen, fluorine or chlorine,
X2 is hydrogen or fluorine, wherein chain L is indicated as defined in claim 2, wherein Rl to R4 are hydrogen and n is 2-10.
9. Compound 1 according to claims 1,2 and 6, characterized by the formula EMI63.1 10. Compound 2 according to claims 1, 2 and 6, characterized by the formula EMI63.2 11. Compound 3 according to claims 1,2 and 6, characterized by the formula EMI63.3 12. Compound 4 according to claims 1,2 and 6, characterized by the formula EMI63.4 13. Compound 5 according to claims 1, 2 and 6, characterized by the formula EMI63.5 14. Compound 6 according to claims 1,2 and 6, characterized by the formula EMI64.1 15. Compound 7 according to claims 1, 2 and 6, characterized by the formula EMI64.2 16. Compound 8 according to claims 1,2 and 6, characterized by the formula EMI64.3 17.
Compound 9 according to claims 1, 2 and 6, characterized by the formula EMI64.4 18. Compound 10 according to claims 1,2 and 6, characterized by the formula EMI65.1 19. Compound 11 according to claims 1, 2 and 6, characterized by the formula EMI65.2 20. Compound 12 according to claims 1,2 and 6, characterized by the formula EMI65.3 21. Compound 13 according to claims 1, 2 and 6, characterized by the formula EMI65.4 22. Compound 14 according to claims 1, 2 and 6, characterized by the formula EMI66.1 23. Compound 15 according to claims 1, 2 and 6, characterized by the formula EMI66.2 24. Compound 16 according to claims 1,2 and 6, characterized by the formula EMI66.3 25.
Compound 17 according to claims 1, 2 and 6, characterized by the formula EMI66.4 26. Compound 18 according to claims 1, 2 and 6, characterized by the formula EMI67.1 27. Compound 19 according to claims 1,2 and 6, characterized by the formula EMI67.2 28. Compound 20 according to claims 1,2 and 6, characterized by the formula EMI67.3 29. Compound 21 according to claims 1,2 and 4, characterized by the formula EMI67.4 30. Compound 22 according to claims 1,2 and 7, characterized by the formula EMI68.1 31. Compound 23 according to claims 1,2 and 7, characterized by the formula EMI68.2 32. Compound 24 according to claims 1, 2 and 7, characterized by the formula EMI68.3 33. Compound 25 according to claims 1,2 and 7, characterized by the formula EMI68.4 34.
Compound 26 according to claims 1,2 and 7, characterized by the formula EMI69.1 35. Compound 27 according to claims 1, 2 and 7, characterized by the formula EMI69.2 36. Compound 28 according to claims 1,2 and 3, characterized by the formula EMI69.3 37.
Process for the preparation of compounds represented by the general structure I wherein all symbols and radicals have the meanings as defined in claims 1 and 2, characterized in that the compounds can be prepared from a corresponding steroid part represented by the structures Al to A4 and A6, wherein all radicals and symbols have the meanings as defined for the substructures Al to A4 and A6, and a macrolide intermediate represented by the structure Mll by linking them via corresponding chains represented by the structure L, whereat for the formation of an amide bond from carboxylic acids of the steroid subunits indicated by the formulas Al to A4 and A6, activation with carboxydiimide and benzotriazole (HOBT) in anhydrous dichloromethane in the presence of a base such as triethylamine at room temperature under the flow of a suitable inert gas is used.
38. Process for the preparation of compounds represented by the general structure I, wherein all symbols and radicals have the meanings as defined in claims 1 and 2, characterized in that the compounds can be prepared from a corresponding steroid part represented by the structures Al to A4 and A6, wherein all radical and symbols have the meanings as defined for the substructures Al to A4 and A6, and a macrolide intermediate represented by the structure M7 by linking them via corresponding chains represented by the structure L, whereat for the formation of an ester bond from carboxylic acids of the steroid subunits indicated by the formulas Al to A4 and A6, a reaction with K2CO3 in anhydrous dimethylformamide in the flow of a suitable inert gas is used.
39. Process for the preparation of compounds represented by the general structure I, wherein all symbols and radicals have the meanings as defined in claims 1 and 2, characterized in that the compounds can be prepared from a corresponding steroid part represented by the structures Al to A4 and A6, wherein all radical and symbols have the meanings as defined for the substructures Al to A4 and A6, and a macrolide intermediate represented by the structure M9 by linking them via corresponding chains represented by the structure L, whereat for the formation of an ester bond from carboxylic acids of the steroid subunits indicated by the formulas Al to A4 and A6, a reaction with K2CO3 in anhydrous dimethylformamide in the flow of a suitable inert gas is used.
40. Process for the preparation of compounds represented by the general structure I, wherein all symbols and radicals have the meanings as stated in claims 1 and 2, characterized in that the compounds can be prepared from a corresponding steroid part represented by the structures Al to A4 and A6, wherein all radical and symbols have the meanings as defined for the substructures Al to A4 and A6, and a macrolide intermediate represented by the structure M10 by linking them via corresponding chains represented by the structure L, whereat for the formation of an ester bond from carboxylic acids of the steroid subunits indicated by the formulas Al to A4 and A6, a reaction with K2CO3 in anhydrous dimethylformamide in the flow of a suitable inert gas is used.
41. Process for the preparation of compounds represented by the general structure I, wherein all symbols and radicals have meanings as defined in claims 1 and 2, characterized in that the compounds can be prepared from a corresponding steroid part represented by the structures Al to A4 and A6, wherein all radical and symbols have the meanings as defined for the substructures Al to A4 and A6, with the synthesis being performed by mixing the steroid intermediate A8 and the macrolide intermediate represented by the structure M12 in acetonitrile at a temperature from 20 to 60 C in the flow of a suitable inert gas.
42. Process for the preparation of compounds represented by the general structure I, wherein all symbols and radicals have the meanings as defined in claims 1 and 2, characterized in that the compounds can be prepared from a corresponding steroid part represented by the structures Al to A4 and A6, wherein all radical and symbols have the meanings as defined for the substructures Al to A4 and A6, with the esterification synthesis being performed using the steroid intermediate A9 and a macrolide having a free reactive hydroxyl group and mixing them with pivaloyl chloride as an activator at room temperature in the presence of a base such as triethylamine in the flow of a suitable inert gas.
43. Use of compounds according to claims 1 to 36 in human or veterinary medicine.
44. Use of compounds according to claims 1 to 36 in therapy of patients with inflammation conditions and diseases.
45. Use of compounds according to claims 1 to 36 in therapy of patients with asthma, allergic rhinitis, nasal polyps, intestinal diseases such as Crohn's disease, colitis, ulcerative colitis, dermatological inflammations such as eczema, psoriasis, allergic dermatitis, neurodermatitis, pruritis, conjunctivitis and rheumatoid arthritis.
46. Use of compounds according to claims 1 to 36 in treatment and prophylaxis of inflammatory conditions and diseases induced by excessive nonregulated production of cytokines and inflammation mediators, wherein the suitable pharmaceutical preparations can be administered topically, parenterally or orally.
47. Use of compounds according to claims 1 to 36 as active substances in pharmaceutical preparations for oral, rectal, parenteral, percutaneous and inhalation application in humans and animals.
PCT/HR2002/000001 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy Ceased WO2002055531A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
SK979-2003A SK9792003A3 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
JP2002556599A JP4474101B2 (en) 2001-01-09 2002-01-03 Complex of immune cell specific macrolide compound and anti-inflammatory compound for improved cell targeting of anti-inflammatory therapy
EA200300781A EA007061B1 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
PL363478A PL207636B1 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
IL15667302A IL156673A0 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
US10/250,934 US7446097B2 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
AT02729470T ATE462713T1 (en) 2001-01-09 2002-01-03 CONJUGATES OF IMMUNE CELL-SPECIFIC MACROLIDE COMPOUNDS WITH ANTI-PHLOGISTIC COMPOUNDS FOR IMPROVED CELL-DIRECTED ANTI-PHLOGISTIC THERAPY
BR0206347-6A BR0206347A (en) 2001-01-09 2002-01-03 Immune cell-specific macrolide compounds conjugates with anti-inflammatory compounds for improved cellular objectification of anti-inflammatory therapy
EEP200300293A EE05333B1 (en) 2001-01-09 2002-01-03 Conjugates of macrolide compounds with anti-inflammatory agents and their use
HU0500180A HUP0500180A3 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
DE60235794T DE60235794D1 (en) 2001-01-09 2002-01-03 CONJUGATES OF IMMUNETIC-SPECIFIC MACROLIDE COMPOUNDS WITH ANTI-PHLOGISTIC COMPOUNDS FOR IMPROVED CELL-DRIVEN ANTI-PHLOGISTIC THERAPY
CA002434009A CA2434009C (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
HK04108052.4A HK1065320B (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
EP02729470A EP1351973B1 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
UA2003076135A UA77166C2 (en) 2001-01-09 2002-03-01 Conjugates between macrolids specific for immune cells and anti-inflammatory compounds for improved targeted anti-inflammatory therapy, method for their preparation (variants)
US12/211,213 US7928078B2 (en) 2001-01-09 2008-09-16 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HRP20010018A 2001-01-09
HR20010018A HRP20010018A2 (en) 2001-01-09 2001-01-09 Novel anti-inflammatory compounds

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10250934 A-371-Of-International 2002-01-03
US12/211,213 Continuation US7928078B2 (en) 2001-01-09 2008-09-16 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy

Publications (1)

Publication Number Publication Date
WO2002055531A1 true WO2002055531A1 (en) 2002-07-18

Family

ID=10947235

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/HR2002/000001 Ceased WO2002055531A1 (en) 2001-01-09 2002-01-03 Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy

Country Status (23)

Country Link
US (2) US7446097B2 (en)
EP (1) EP1351973B1 (en)
JP (1) JP4474101B2 (en)
CN (1) CN1269836C (en)
AR (1) AR035727A1 (en)
AT (1) ATE462713T1 (en)
BG (1) BG108073A (en)
BR (1) BR0206347A (en)
CA (1) CA2434009C (en)
CZ (1) CZ20031825A3 (en)
DE (1) DE60235794D1 (en)
EA (1) EA007061B1 (en)
EE (1) EE05333B1 (en)
ES (1) ES2342364T3 (en)
GE (1) GEP20053607B (en)
HR (1) HRP20010018A2 (en)
HU (1) HUP0500180A3 (en)
IL (1) IL156673A0 (en)
PL (1) PL207636B1 (en)
RS (1) RS51308B (en)
SK (1) SK9792003A3 (en)
UA (1) UA77166C2 (en)
WO (1) WO2002055531A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003070174A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
WO2004005309A3 (en) * 2002-07-08 2004-04-15 Pliva D D Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
WO2004005310A3 (en) * 2002-07-08 2004-04-22 Pliva D D New compounds, compositions and methods for treatment of inflammatory diseases and conditions
US6799183B2 (en) * 2000-09-29 2004-09-28 Hitachi, Ltd. Operation assistance method and system and recording medium for storing operation assistance method
WO2004094449A1 (en) * 2003-04-24 2004-11-04 Pliva-Istrazivacki Institut D.O.O. Macrolide-conjugates with anti-inflammatory activity
WO2004005313A3 (en) * 2002-07-08 2005-04-21 Pliva Istrazivacki Inst D O O Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
JP2005200318A (en) * 2004-01-14 2005-07-28 Shionogi & Co Ltd Erythromycin derivative
WO2006046123A3 (en) * 2004-10-27 2006-07-06 Pliva Istrazivacki Inst D O O Conjugates with anti-inflammatory activity
WO2006018698A3 (en) * 2004-08-12 2006-12-28 Glaxosmithkline Zagreb Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
US7271154B2 (en) 2002-02-15 2007-09-18 Merckle Gmbh Antibiotic conjugates
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
WO2011116312A1 (en) * 2010-03-19 2011-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
US8357506B2 (en) 2002-02-15 2013-01-22 Michael Burnet Method of identifying improved conjugates of biologically active compounds
WO2017085329A1 (en) * 2015-11-19 2017-05-26 Epi-Endo Pharmaceuticals Ehf. Azithromycin derivatives with epithelial barrier enhancement properties
EP3309166A2 (en) * 2013-01-23 2018-04-18 Sphaera Pharma Pvt. Ltd. 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
US11542298B2 (en) 2014-07-23 2023-01-03 Epirium Bio Inc. Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
WO2023248010A3 (en) * 2022-06-23 2024-03-07 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183696A1 (en) * 2004-08-12 2006-08-17 Pliva-Istrazivacki Institut D.O.O. Use of immune cell specific conjugates for treatment of inflammatory diseases of gastrointestinal tract
US20080249034A1 (en) * 2005-03-21 2008-10-09 Zambon S.P.A. Use of Macrolides for Treating Intestinal Inflammation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163124A (en) * 1987-12-21 1989-06-27 Yamayuu Seikatsushiya:Kk Analgesic, anti-inflammatory, antitumor suppurative of external use
WO1997041255A1 (en) * 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Three-hybrid screening assay
FR2776927A1 (en) * 1998-04-07 1999-10-08 Univ Paris Curie COMPOSITIONS FOR VECTORIZING MOLECULES
WO1999064040A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel polyene macrolide compounds and uses

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710495A (en) 1980-07-10 1987-12-01 Otsuka Pharmaceutical Co., Ltd. Soft steroids having anti-inflammatory activity
HU198913B (en) 1987-09-03 1989-12-28 Pliva Pharm & Chem Works Process for producing 10-dihydro-10-deoxo-11-aza-erythronolide a-derivatives and pharmaceutical compositions containing them as active components
SE9100342D0 (en) 1991-02-04 1991-02-04 Astra Ab NOVEL STEROID ESTERS
SE9100341D0 (en) 1991-02-04 1991-02-04 Astra Ab NOVEL STEROIDS
GB9225923D0 (en) 1992-12-11 1993-02-03 Rhone Poulenc Rorer Ltd New compositions of matter
DE69311742T2 (en) 1992-12-24 1998-01-08 Rhone Poulenc Rorer Ltd NEW STEROIDS
AU3192695A (en) 1994-08-12 1996-03-07 Taisho Pharmaceutical Co., Ltd. Interleukin-5 production inhibitor
WO1996004919A1 (en) 1994-08-12 1996-02-22 Taisho Pharmaceutical Co., Ltd. Interleukin-5 production inhibitor
DE19542949A1 (en) 1995-11-17 1997-07-17 Hilti Ag Bolt for driving into hard materials
US6288234B1 (en) * 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
IT1306205B1 (en) 1999-01-15 2001-05-30 Zambon Spa MACROLIDS WITH ANTI-INFLAMMATORY ACTIVITY.
AU2003219770B2 (en) 2002-02-15 2008-10-09 Merckle Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01163124A (en) * 1987-12-21 1989-06-27 Yamayuu Seikatsushiya:Kk Analgesic, anti-inflammatory, antitumor suppurative of external use
WO1997041255A1 (en) * 1996-04-26 1997-11-06 Massachusetts Institute Of Technology Three-hybrid screening assay
FR2776927A1 (en) * 1998-04-07 1999-10-08 Univ Paris Curie COMPOSITIONS FOR VECTORIZING MOLECULES
WO1999064040A1 (en) * 1998-06-08 1999-12-16 Advanced Medicine, Inc. Novel polyene macrolide compounds and uses

Non-Patent Citations (24)

* Cited by examiner, † Cited by third party
Title
ANTIINFECT. DRUGS CHEMOTHER. (1996), 14(2), 137-146 *
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. UNITED STATES OCT 1997, vol. 41, no. 10, October 1997 (1997-10-01), pages 2099 - 2107, ISSN: 0066-4804 *
D. ROMO ET AL: "Total Synthesis and Immunosuppressive Activity of (-)-Pateamine A and Related Compounds: Implementation of beta-Lactam Based Macrolzyztion", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY., vol. 120, no. 47, 1998, AMERICAN CHEMICAL SOCIETY, WASHINGTON, DC., US, pages 12237 - 12254, XP002200620, ISSN: 0002-7863 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1988, ANDERSON R ET AL: "AN IN-VITRO EVALUATION OF THE CELLULAR UPTAKE AND INTRAPHAGOCYTIC BIOACTIVITY OF CLARITHROMYCIN A-56268 TE-031 A NEW MACROLIDE ANTIMICROBIAL AGENT", XP002200624, Database accession no. PREV198987045431 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ABDELGHAFFAR, HOURIA ET AL: "Erythromycin A-derived macrolides modify the functional activities of human neutrophils by altering the phospholipase D-phosphatidate phosphohydrolase transduction pathway. L-Cladinose is involved both in alterations of neutrophil functions and modulation of this transductional pathway", XP002200631, retrieved from STN Database accession no. 127:341381 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; GRIFFITH, ERIC C. ET AL: "Yeast three-hybrid system for detecting ligand-receptor interactions", XP002200621, retrieved from STN Database accession no. 135:147811 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IANARO, ANGELA ET AL: "Anti- inflammatory activity of macrolide antibiotics", XP002200630, retrieved from STN Database accession no. 132:160867 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IWAKI, RIICHIRO: "Analgesic, antiinflammatory, and pus-removing pharmaceuticals", XP002200623, retrieved from STN Database accession no. 112:104876 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SCHENTAG, J. J. ET AL: "Relationships between serum, intracellular, and infection site concentrations of macrolide and azalide antibiotics. A theoretical exploration of the concept of white blood cell drug delivery to infection sites", XP002200622, retrieved from STN Database accession no. 126:135534 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; TRAVERS, JEFFREY B.: "Novel immunomodulators for topical skin disease therapy", XP002200632, retrieved from STN Database accession no. 132:189221 *
DATABASE MEDLINE [online] 1997, GEERDES-FENGE H F ET AL: "Comparative pharmacokinetics of dirithromycin and erythromycin in normal volunteers with special regard to accumulation in polymorphonuclear leukocytes and in saliva.", XP002200627, Database accession no. NLM9403284 *
DATABASE MEDLINE [online] February 1997 (1997-02-01), FIETTA A ET AL: "Requirements for intracellular accumulation and release of clarithromycin and azithromycin by human phagocytes.", XP002200625, Database accession no. NLM9106014 *
DATABASE MEDLINE [online] June 1999 (1999-06-01), SCORNEAUX B ET AL: "Intracellular accumulation, subcellular distribution, and efflux of tilmicosin in bovine mammary, blood, and lung cells.", XP002200628, Database accession no. NLM10386306 *
DATABASE MEDLINE [online] March 1999 (1999-03-01), KHOSLA R ET AL: "Streptogramins: a new class of antibiotics.", XP002200629, Database accession no. NLM10798011 *
DATABASE MEDLINE [online] October 1997 (1997-10-01), VAZIFEH D ET AL: "Cellular accumulation of the new ketolide RU 64004 by human neutrophils: comparison with that of azithromycin and roxithromycin.", XP002200626, Database accession no. NLM9333032 *
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. GERMANY 1997, vol. 53, no. 2, 1997, pages 127 - 133, ISSN: 0031-6970 *
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2000), 9(3), 529-542 *
INDIAN JOURNAL OF MEDICAL SCIENCES. INDIA MAR 1999, vol. 53, no. 3, March 1999 (1999-03-01), pages 111 - 119, ISSN: 0019-5359 *
J. IMMUNOL. (1997), 159(8), 3995-4005 *
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, vol. 22, no. 6, 1988, pages 923 - 934, ISSN: 0305-7453 *
JOURNAL OF CHEMOTHERAPY (FLORENCE, ITALY) ITALY FEB 1997, vol. 9, no. 1, February 1997 (1997-02-01), pages 23 - 31, ISSN: 1120-009X *
JOURNAL OF DAIRY SCIENCE. UNITED STATES JUN 1999, vol. 82, no. 6, June 1999 (1999-06-01), pages 1202 - 1212, ISSN: 0022-0302 *
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2000), 292(1), 156-163 *
METHODS IN ENZYMOLOGY (2000), 328(APPLICATIONS OF CHIMERIC GENES AND HYBRID PROTEINS, PT. C), 89-103 *

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6799183B2 (en) * 2000-09-29 2004-09-28 Hitachi, Ltd. Operation assistance method and system and recording medium for storing operation assistance method
WO2003070174A2 (en) 2002-02-15 2003-08-28 Sympore Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
US8357506B2 (en) 2002-02-15 2013-01-22 Michael Burnet Method of identifying improved conjugates of biologically active compounds
US7579324B2 (en) 2002-02-15 2009-08-25 C-A-I-R Biosciences Gmbh Conjugates of biologically active compounds, methods for their preparation and use, formulation and pharmaceutical applications thereof
EP1483277A4 (en) * 2002-02-15 2007-10-03 Merckle Gmbh CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS, METHODS OF PREPARATION AND USE, AND FORMULATION AND PHARMACEUTICAL APPLICATIONS
US7271154B2 (en) 2002-02-15 2007-09-18 Merckle Gmbh Antibiotic conjugates
US7091187B2 (en) 2002-07-08 2006-08-15 Pliva-Istrazivacki Institut D.O.O. Compounds, compositions and methods for treatment of inflammatory diseases and conditions
WO2004005310A3 (en) * 2002-07-08 2004-04-22 Pliva D D New compounds, compositions and methods for treatment of inflammatory diseases and conditions
WO2004005309A3 (en) * 2002-07-08 2004-04-15 Pliva D D Novel nonsteroidal anti-inflammatory substances, compositions and methods for their use
US7109176B2 (en) 2002-07-08 2006-09-19 Pliva-Istrazivacki Institut D.O.O. Nonsteroidal anti-inflammatory substances, compositions and methods for their use
WO2004005313A3 (en) * 2002-07-08 2005-04-21 Pliva Istrazivacki Inst D O O Hybrid molecules of macrolides with steroid/non-steroid anti-inflammatory, antineoplastic and antiviral active molecules
US7157433B2 (en) 2002-07-08 2007-01-02 Glaxosmithkline Istrazivacki Centar Zagreb Compounds, compositions as carriers for steroid/nonsteroid anti-inflammatory; antienoplastic and antiviral active molecules
JP2006524221A (en) * 2003-04-24 2006-10-26 プリヴァ−イストラジヴァキ・インスティトゥ・ディー・オー・オー Macrolide conjugates with anti-inflammatory activity
WO2004094449A1 (en) * 2003-04-24 2004-11-04 Pliva-Istrazivacki Institut D.O.O. Macrolide-conjugates with anti-inflammatory activity
CN100393741C (en) * 2003-04-24 2008-06-11 葛兰素伊斯特拉齐瓦基森塔萨格勒布公司 Macrolide complexes with anti-inflammatory activity
EP2070940A1 (en) 2003-04-24 2009-06-17 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Compounds with anti-inflammatory activity
US7579334B2 (en) 2003-04-24 2009-08-25 Glaxosmithkline Istrazivacki Centar Zagreb Compounds with anti-inflammatory activity
KR101107336B1 (en) 2003-04-24 2012-01-19 글락소 그룹 리미티드 Macrolide-conjugates with anti-inflammatorory activity
US7276487B2 (en) 2003-09-23 2007-10-02 Enanta Pharmaceuticals, Inc. 9a, 11-3C-bicyclic 9a-azalide derivatives
JP2005200318A (en) * 2004-01-14 2005-07-28 Shionogi & Co Ltd Erythromycin derivative
WO2006018698A3 (en) * 2004-08-12 2006-12-28 Glaxosmithkline Zagreb Use of cell-specific conjugates for treatment of inflammatory diseases of the gastrointestinal tract
US7402568B2 (en) 2004-09-29 2008-07-22 Enanta Pharmaceuticals, Inc. Bicyclic 9a-azalide derivatives
EP2196469A1 (en) 2004-10-27 2010-06-16 GlaxoSmithKline istrazivacki centar Zagreb d.o.o. Conjugates with anti-inflammatory activity
WO2006046123A3 (en) * 2004-10-27 2006-07-06 Pliva Istrazivacki Inst D O O Conjugates with anti-inflammatory activity
US7271155B2 (en) 2005-01-07 2007-09-18 Enanta Pharmaceuticals, Inc. 9A, 11-2C-bicyclic 9a-azalide derivatives
WO2011116312A1 (en) * 2010-03-19 2011-09-22 Catabasis Pharmaceuticals, Inc. Fatty acid macrolide derivatives and their uses
EP3309166A2 (en) * 2013-01-23 2018-04-18 Sphaera Pharma Pvt. Ltd. 11beta-hydroxy-steroids for use in mitochondria biogenesis and diseases associated with mitochondrial dysfunction or depletion
US11542298B2 (en) 2014-07-23 2023-01-03 Epirium Bio Inc. Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
WO2017085329A1 (en) * 2015-11-19 2017-05-26 Epi-Endo Pharmaceuticals Ehf. Azithromycin derivatives with epithelial barrier enhancement properties
CN108290919A (en) * 2015-11-19 2018-07-17 艾比恩多制药有限责任公司 Azithromycin derivatives with epithelial barrier enhancing properties
US10723752B2 (en) 2015-11-19 2020-07-28 Epiendo Pharmaceuticals Ehf Azithromycin derivatives with epithelial barrier enhancement properties
US11236120B2 (en) 2015-11-19 2022-02-01 Epiendo Pharmaceuticals Ehf Azithromycin derivatives with epithelial barrier enhancement properties
CN108290919B (en) * 2015-11-19 2022-06-17 艾比恩多制药有限责任公司 Azithromycin derivatives having epithelial barrier enhancing properties
US12049477B2 (en) 2015-11-19 2024-07-30 Epiendo Pharmaceuticals Ehf. Azithromycin derivatives with epithelial barrier enhancement properties
WO2023248010A3 (en) * 2022-06-23 2024-03-07 Synovo Gmbh Targeted modulators of jak3 for treatment of inflammatory and autoimmune diseases

Also Published As

Publication number Publication date
US20040198677A1 (en) 2004-10-07
CA2434009A1 (en) 2002-07-18
IL156673A0 (en) 2004-01-04
HK1065320A1 (en) 2005-02-18
ATE462713T1 (en) 2010-04-15
EE05333B1 (en) 2010-08-16
SK9792003A3 (en) 2004-01-08
EE200300293A (en) 2003-10-15
HRP20010018A2 (en) 2002-12-31
EP1351973B1 (en) 2010-03-31
CZ20031825A3 (en) 2003-11-12
CN1491230A (en) 2004-04-21
YU55203A (en) 2006-03-03
AR035727A1 (en) 2004-07-07
HUP0500180A2 (en) 2006-09-28
ES2342364T3 (en) 2010-07-06
PL207636B1 (en) 2011-01-31
HUP0500180A3 (en) 2009-12-28
CA2434009C (en) 2009-09-29
DE60235794D1 (en) 2010-05-12
JP4474101B2 (en) 2010-06-02
US7446097B2 (en) 2008-11-04
GEP20053607B (en) 2005-09-12
EA007061B1 (en) 2006-06-30
UA77166C2 (en) 2006-11-15
US7928078B2 (en) 2011-04-19
EA200300781A1 (en) 2003-12-25
EP1351973A1 (en) 2003-10-15
PL363478A1 (en) 2004-11-15
BR0206347A (en) 2004-02-10
CN1269836C (en) 2006-08-16
BG108073A (en) 2005-05-31
RS51308B (en) 2010-12-31
US20090105163A1 (en) 2009-04-23
JP2004518670A (en) 2004-06-24

Similar Documents

Publication Publication Date Title
US7928078B2 (en) Conjugates of immune cell specific macrolide compounds with anti-inflammatory compounds for improved cellular targeting of anti-inflammatory therapy
US7091187B2 (en) Compounds, compositions and methods for treatment of inflammatory diseases and conditions
EP1551865B1 (en) Hybrid molecules of macrolides with steroidal/non-steroidal anti-inflammatory molecules
US20090221543A1 (en) New corticosteroids
PT749437E (en) PHARMACEUTICAL USES OF STEROID DERIVATIVES
US20050176694A1 (en) Pharmaceutical compounds
RU2462472C2 (en) Chemical compounds
JP4613366B2 (en) Macrolide conjugates with anti-inflammatory activity
AU2003210161A1 (en) New corticosteroids
WO2014207309A1 (en) Therapeutically active estratrienthiazole derivatives as inhibitors of 17 b-hydroxysteroid dehydrogenase, type 1
EP1805202B1 (en) Conjugates with anti-inflammatory activity
ES2943573B2 (en) Process for the preparation of 21-(acetyloxy)-17-(1-oxopropoxy)-pregn-4-ene-3,20-dione
US4810701A (en) 11-desoxy-17α-hydroxycorticosterone derivatives
US4933332A (en) 11-desoxy-17-α-hydroxycorticosterone derivatives

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-552/03

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): BA BG BR CA CN CZ EE GE HU IL IN IS JP KP LT LV MK PL SI SK UA US UZ YU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 156673

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: PV2003-1825

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2434009

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002556599

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002729470

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1176/CHENP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 9792003

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 10807302

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 02804715X

Country of ref document: CN

Ref document number: 7074

Country of ref document: GE

Ref document number: 5260

Country of ref document: GE

Ref document number: 200300781

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2002729470

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-1825

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 10250934

Country of ref document: US